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ABSTRACT OF DISSERTATION

COMPUTATIONAL MODELING, DESIGN, AND CHARACTERIZATION OF
COCAINE-METABOLIZING ENZYMES FOR ANTI-COCAINE
MEDICATION
Cocaine is a widely abused and addictive drug, resulting in serious
medical and social problems in modern society. Currently, there is no FDAapproved medication specific for cocaine abuse treatment. The disastrous medical
and social consequences of cocaine abuse have made the development of an anticocaine medication a high priority. However, despite decades of efforts,
traditional pharmacodynamic approach has failed to yield a truly useful smallmolecule drug due to the difficulties inherent in blocking a blocker like cocaine
without affecting the normal functions of the transporters or receptors. An
alternative approach, i.e. pharmacokinetic approach, is to interfere with the
delivery of cocaine to its receptors/transporters and/or accelerate its metabolism in
the body. It would be an ideal anti-cocaine medication to accelerate cocaine
metabolism producing biologically inactive metabolites.
Two natural enzymes may catalyze hydrolysis of cocaine: human
butyrylcholinesterase (BChE) and bacterial cocaine esterase (CocE). However,
the wild-type enzymes are not suitable as anti-cocaine therapeutics, due to the low
catalytic activity, thermoinstability, or short biological half-life. In this
investigation, we performed integrated computational-experimental studies to
rationally design and discover mutants of these enzymes in order to improve the
catalytic activity, thermostability, and/or biological half-life. To rationally design
desirable mutants of the enzymes, we have successfully developed computational
models, including those for BChE gating, glycosylated BChE structure, BChEsubstrate complex structures, BChE dimer/tetramer structures, CocE
monomer/dimer structures, and CocE-substrate complex structures. Development
of the computational models enabled us to rationally design new amino-acid
mutations that may improve the catalytic activity, thermostability, and/or
prolonged biological half-life. The computational design was followed by wet
experimental tests, including both in vitro and in vivo experiments, leading to
discovery of new enzyme forms with not only a high catalytic efficiency against
cocaine, but also an improved thermostability and/or prolonged biological halflife. The identified new mutants of BChE and CocE are expected to be valuable
candidates for development of a more efficient enzyme therapy for cocaine abuse.
The encouraging outcomes of the present study also suggest that the structureand-mechanism-based design and integrated computational-experimental
approach is promising for rational drug design and discovery.

KEYWORDS: Protein drug design, Human butyrylcholinesterase, Bacterial
cocaine esterase, Mutant, Anti-Cocaine
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Chapter One: Cocaine Abuse and Anti-Cocaine Medication

Cocaine is a widely abused and addictive drug which blocks dopamine reuptake
in the central nervous system (CNS). Currently, there is no FDA-approved medication
specific for cocaine abuse treatment. The disastrous medical and social consequences of
cocaine abuse have made the development of an anti-cocaine medication a high priority.
However, despite decades of efforts, traditional pharmacodynamic approach has failed to
yield a truly useful small-molecule drug due to the difficulties inherent in blocking a
blocker like cocaine without affecting the normal functions of the receptors or
transporters

(such

as

dopamine

transporter).

An

alternative

approach,

i.e.

pharmacokinetic approach, is to interfere with the delivery of cocaine to its receptors
and/or accelerate its metabolism in the body. It would be an ideal anti-cocaine medication
to accelerate cocaine metabolism producing biologically inactive metabolites. Two
natural enzymes, i.e. human butyrylcholinesterase (BChE) and bacterial cocaine esterase
(CocE), can catalyze hydrolysis of cocaine into non-toxic metabolites, demonstrating
their potential in anti-cocaine medication.

1.1 Cocaine and its abuse
Cocaine is a natural alkaloid found in the coca plant (mainly from Erythroxylum
coca and Erythroxylum novogranatense) originally from Andean ridge in South America,
and normally extracted from plant leaves.1,2 The ancient Inca Indians grew coca for both
medical purpose and religious rituals for a long history due to its ability to boost energy,
relieve fatigue, and lessen hunger.1,3 As the discovery of the new world in sixteenth
century, coca plant is known by the outside world. However, the content of cocaine in
coca leaves decreases significantly during storage,4 it was not until 1855 that this alkaloid
was isolated by a German chemist Friedrich Gaedcke with the name of “erythroxyline”.5
Albert Niemann further improved the purification process of this alkaloid in 1859 and
named it with the current name “cocaine”.2,6
1

Before the isolation of cocaine, chewing coca leaves is the main form of
consuming cocaine. In fact, due to the low gastrointestinal absorption of cocaine and the
relatively low content of cocaine in coca leaves (about 1% of the weight of the leaves),
chewing coca leaves does not cause the toxicity associated with purified cocaine.3
Currently, there are two forms of cocaine, including salt and base. Cocaine hydrochloride
is the most common salt and is the main form in the street until the late 1970s. It is a
water-soluble powder, normally used nasally or mixed with water and injected
intravenously.7 The high melting temperature (195 ºC) of the salt makes it not suitable to
be smoked because it will decompose before vaporization. Cocaine base is the alkaloid
form of cocaine including freebase and “crack”, mainly emerging in the street after 1970s.
Crack cocaine is in fact a low purity form of freebase cocaine, and is named from the
sound of cocaine crystals popping during preparation. Freebase and crack cocaine are
insoluble in water, making it difficult for injection. However, the relatively low melting
temperature (98ºC) makes it easily be smoked.

Figure 1.1 Molecular structure of (-)-cocaine free base.

Cocaine has limited medical use as a local anesthetic (in dentistry and
ophthalmology). More importantly, it is a CNS stimulant. Consuming cocaine in any
aforementioned forms, either by nasal insufflation, intravenous injection, or smoking, can
lead to the feeling of euphoria or “high”. Depending on the route of administration and
the dosage, cocaine can take effect in from less than one minute to around 15 minutes and
last for 15 minutes to one hour.8 Besides the feeling of euphoria, effects of cocaine also
include feeling of energetic, talkative, increased alertness, reduced appetite, and sensation
of light, sound and touch.9 Long-term use of cocaine could cause serious physical
2

problems, including cardiovascular failures, respiratory difficulties, and gastrointestinal
complications, and mental problems, including depression, agitation, nervous, and tired
but unable to sleep.3 Cocaine overdose could be more serious and even lethal, due to the
possible respiratory failure, stroke, cerebral hemorrhage, or heart-failure after seizures
induced by cocaine’s toxicity.10,11
As the addictive and toxic properties of cocaine have been known, the production,
distribution, and sale of cocaine products are restricted in most countries.12 However,
cocaine abuse is still a widespread problem throughout society.12

1.2 Mechanism for the action of cocaine
Cocaine is a powerful CNS stimulant, causing its reinforcing and toxic effects by
binding with various monoaminergic neurotransmitter systems, such as dopaminergic,13,14
serotoninergic,15 and norepinephrinergic16 systems. The most important target of cocaine
is the dopamine transporter (DAT).17 During the normal dopaminergic signaling cycle,
neurotransmitter dopamine (DA) is released into synaptic cleft from the transmitting
neuron and binds with dopamine receptors on the receiving neuron to conduct the
signaling. Dopamine will be then recycled via DAT located on the transmitting neuron to
end the signaling cycle. However, cocaine entering into the brain would interfere with
this signaling cycle. It will bind with the DAT to form a complex that can block the
binding of dopamine.17 This can result in accumulation of dopamine in the synaptic cleft
and lead to the prolonged and enhanced effect of dopaminergic signaling, which causes
the euphoria feeling as reported by cocaine users.
Moreover, one-time use of cocaine could cause the change of the dopaminergic
signaling, i.e. the down-regulation of dopamine receptors and up-regulation of dopamine
transporter for at least a month.18 So, cocaine user would not achieve the same “high” as
they felt at the first time they used the drug. As normalization of the dopaminergic
function is usually an extremely slow process, there is less dopamine in the synapse for
signaling in the brain of a cocaine user. Gradually, a tolerance to the drug will be
developed, leading to the drug seeking or carving. So, it is necessary for therapeutic
treatment of cocaine addiction to first (directly or indirectly) block the stimulant effects
3

of cocaine. Without the stimulant effects of cocaine, there would be a better chance to
bring the function of brain's communication system back to normal.19
Besides affecting the neurological system, cocaine also has a severe impact to the
cardiovascular system. Increased heart rate, blood pressure, and vasoconstriction are
caused by cocaine binding with noradrenergic transporters to result in elevated
noradrenergic signaling.20 Cocaine also binds to sodium ion channel, which are
responsible for the local anesthesia and may contribute to cardiac arrhythmias.21

1.3 Treatment of cocaine abuse
Cocaine is now widely abused all over the world with an estimated annual
cocaine users ranging from 13.3 million to 19.7 million in 2010, especially in North
American which is the world's largest consumer of cocaine.12 Cocaine is now the second
most popular illegal recreational drug in the United States behind marijuana and the most
co-abused drug along with alcohol.20 However, it accounts for nearly half of all the
emergency department (ED) visits involving the use of illicit drugs in 2008.20 Cocaine
abuse has resulted in serious medical and social problems in modern society.22,23
Currently, there is no anti-cocaine medication approved by the U.S. Food and Drug
Administration (FDA). So cocaine abuse has made the development of an effective
pharmacological treatment a high priority. Both pharmacodynamics and pharmacokinetic
method have been attempted to search for possible candidates of anti-cocaine
therapeutics.22,24

1.3.1 Pharmacodynamics method
Traditional pharmacodynamic method was used to find small-molecule agents
that are either to block cocaine binding with DAT or alter the effects of cocaine by acting
at sites other than DAT.22,25 For example, vanoxerine (GBR-12909), a selective DAT
inhibitor with a high affinity, was shown to compete with cocaine at the binding of DAT
as a promising candidate. However, due to its cardiovascular side effects, the US
National Institute on Drug Abuse (NIDA) discontinued its clinical trials (from 20032008).25 Tetrahydropalmatine (THP), a non-selective DA receptor antagonist, was shown
4

efficacy in reducing craving and lowered opiate withdrawal symptoms in heroin addicts.
It is now in Phase I human clinical trial for treatment of cocaine addiction.26 Atomoxetine,
a norepinephrine re-uptake inhibitor finished its Phase II clinical trial in 2012 as a
potential therapeutic compound of cocaine abuse in patients with ADHD.27 Beside these
agents, more small-molecule based agents are under different phases of clinical trials.25,26
However, though tried for a long time, due to the complex interrelations of neuronal
circuits, it is very challenging to find a safe and specific therapeutic agent against cocaine
through a pharmacodynamics-based method.

1.3.2 Pharmacokinetic method
Altering the pharmacokinetics of cocaine as treatment of cocaine abuse is gaining
more and more attention in recent years.24,28 Pharmacokinetic method aims to interfere
with the delivery of cocaine to its sites of action and/or accelerate its metabolism in the
body through protein therapeutics including immunological or enzyme strategy.
Immunological strategy aims at searching for protein biologics to sequester
cocaine (via binding with an antibody).29 Passive immunization with monoclonal
antibodies was developed and shown to reduce cocaine self-administration in rats.30 The
most effective active immunization vaccine to date is TA-CD, a Succinyl NorcocaineCholera Toxin B Vaccine.29 According to the clinical trials, reduced cocaine use was
observed in subjects with a reasonably high (43 g/mL) IgG anti-cocaine antibody
levels, which is only attained by 38% of the vaccinated subjects.31 Report also showed
that antibody response of most subjects is 6 weeks later, and cannot last for longer than
12 weeks.31 The major disadvantage of the antibody strategy is that each antigen-binding
site of the antibody can bind with only one cocaine molecule. Catalytic antibody might be
another direction, which can not only sequester cocaine but can accelerate cocaine
metabolism. The most efficient anti-cocaine catalytic antibody reported so far is 15A10.32
It can block the reinforcing effects of cocaine self-administration in rat models and
reduced cocaine-induced seizures and deaths in a dose-dependent manner.32 However, the
catalytic efficiency of the catalytic antibody is very low (KM = 220 μM and kcat = 2.3
min−1).33 Immunological strategy has shown some potential in anti-cocaine medication,
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especially for cocaine addiction patients which have relatively low plasma cocaine
concentration (1-5 µM).19 However, it still has limitation in treating cocaine overdose
patients with plasma cocaine concentration around 3-200 µM.19 In addition, improved
vaccines and boosters are necessary to adequately block the effects of cocaine.31
Compared with immunological strategy, developing a highly efficient cocaine
hydrolase can be a more promising direction.19,20,22,28,34 The desired therapeutic enzymes
can hydrolyze cocaine in the serum with the high efficiency before it reaches its sites of
action to avoid the cocaine toxicity, and can free itself for further binding with and
hydrolyzing another cocaine molecule. Before searching for qualified candidates, it is
necessary to understand the metabolic pathways of cocaine in human. There are two ester
groups in cocaine, benzoyl ester and methyl ester. Benzoyl ester hydrolysis generates
ecgonine methyl ester (EME), whereas methyl ester hydrolysis yields benzoylecgonine
(BE).23 In human, it is estimated that hydrolysis accounts for about 95% of cocaine
metabolism in human.22,35 Human butyrylcholinesterase (BChE) is the principal cocaine
hydrolase in plasma which is capable of hydrolyzing cocaine at the benzoyl ester,36 while
two liver carboxylesterases, known as hCE-1 nd hCE-2, are responsible for hydrolyzing
cocaine at the methyl ester and benzoyl ester, respectively.22,37 The remaining 5% is
deactivated through oxidation by the liver microsomal cytochrome P450 system,
producing norcocaine.22,23 Among the metabolites (EME, BE, and norcocaine), EME
appears to be the least pharmacologically active and may even cause vasodilation,38
whereas both BE and norcocaine appear to cause vasoconstriction and lower the seizure
threshold, similar to cocaine itself.22,38-40 Moreover, norcocaine is hepatotoxic and a local
anesthetic.22,41,42 Clearly, amplifying the metabolic pathway through hydrolysis at the
cocaine benzoyl ester is most suitable for rapid cocaine clearance in the body. Currently,
human BChE and bacterial cocaine esterase (CocE) are the two most interesting
candidate enzymes.20,28 These enzymes will be discussed further in the following sections.
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1.4 Human butyrylcholinesterase as a possible therapeutic enzyme for treatment of
cocaine abuse
Human butyrylcholinesterase (BChE) is a plasma enzyme widely distributed in
the body, and the only substrate in the body is acetylcholine.23 The biological function of
BChE is not completely clear yet;23 studies have suggested that it may be involved in the
regulation of cell proliferation and differentiation during early neuronal development, and
neurodegenerative disorders such as Alzheimer's disease.43,44 On the other hand, human
BChE has a long history of clinical use in treating patients incapable of hydrolyzing
succinylcholine and mivacurium, and no adverse effects have been observed.45,46

Figure 1.2 Structure of human butyrylcholinesterase (PDB ID: 1P0M47) in ribbon model.

Many studies have demonstrated that administration of an exogenous enzyme
(human BChE purified from donated human blood) substantially decreases cocaine’s
half-life.23 Beside, BChE has potential advantages over active immunization since its
administration would immediately enhance cocaine metabolism and would not require an
immune response to be effective which is important for patients with cocaine overdose in
ED.28 Combining all these reasons, enhancement of cocaine metabolism by
administration of BChE is considered as a promising pharmacokinetic approach for the
treatment of cocaine abuse. However, the catalytic activity of this plasma enzyme against
naturally occurring (-)-cocaine (KM = 4.5 μM and kcat = 4.1 min−1) is three orders of
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magnitude lower than that against the biologically inactive (+)-cocaine enantiomer (KM =
6400 μM and kcat = 4.7 min−1).19,48 (+)-Cocaine can be cleared from plasma in seconds
and prior to partitioning into the CNS, whereas (-)-cocaine has a plasma half-life of
approximately 47 min or longer (for an intravenous dose of cocaine 0.2 mg/kg), long
enough for the manifestation of the CNS effects, which peak in minutes.49 Thus, positron
emission tomography (PET) mapping of the binding of (-)-cocaine and (+)-cocaine in
baboon CNS showed marked uptake corresponding to (-)-cocaine at the striatum along
with other areas of low uptake, whereas no CNS uptake corresponding to (+)-cocaine was
observed. (+)-cocaine was hydrolyzed by BChE so rapidly that it never reached the CNS
for PET visualization.50 Furthermore, the actual half-life of (-)-cocaine in plasma is
dependent on the dose of cocaine received.19 When the enzyme is saturated, the (-)cocaine hydrolysis speed has already reached its maximum and will no longer change by
increasing dose of (-)-cocaine. Thus, the higher the dose, the longer the actual half-life of
(-)-cocaine in plasma in the case of cocaine overdose.19,34

1.5 Bacterial cocaine esterase as a possible therapeutic enzyme for treatment of
cocaine abuse
Besides BChE, bacterial cocaine esterase (CocE) found in Rhodococcus spp.
strain MB1 from the rhizosphere soil of coca plant can also hydrolyze the benzoyl ester
of (-)-cocaine (KM = 640 nM and kcat = 468 min−1).51 Therefore, the catalytic efficiency
(kcat/KM) of native CocE is approximately 800-fold higher than that of native BChE
against (-)-cocaine. Studies have shown that CocE can help prevent acute cocaine toxicity
from a lethal dose of cocaine.52 CocE has a relatively short half-life in vivo. In rat, CocE
has a biological half-life of approximately 10 min.53 In addition, being a bacterial protein,
CocE may elicit a robust immune response.34
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Figure 1.3 Structure of cocaine esterase (PDB ID: 3I2F54) in ribbon model.

1.6 Further development of the therapeutic enzymes
Regarding the use of these two enzymes in anti-cocaine therapeutic treatment
development, both BChE and CocE have their own advantages and disadvantages. BChE
from human source can be well tolerated in humans, but the low catalytic efficiency of
native BChE against naturally occurring (-)-cocaine must be improved. Compared with
native BChE, the catalytic efficiency of native CocE against (-)-cocaine is approximately
800-fold higher. The disadvantages of using native CocE are related to its bacterial origin
and thermoinstability.53 In addition, both BChE (recombinant form of the protein) and
CocE have short biological half-lives in animal models.53,55 But the biological half-lives
could be prolonged through protein engineering. Hence, both BChE and CocE could be
engineered to become valuable anti-cocaine therapeutic agents and could complement
each other.
In recent years, our research group has successfully designed a series of BChE
mutants with a considerably improved catalytic efficiency against (-)-cocaine based on
the understanding of catalytic mechanism of the enzymatic cocaine hydrolysis using an
integrated computational-experimental approach.56-60 One of the BChE mutants designed
in our group, i.e. A199S/S287G/A328W/Y332G BChE (denoted as E14-3), fused with
human serum albumin (denoted as AlbuBChE) is under human clinical trial by Teva
Pharmaceutical Industries Ltd; the Phase II trial has been completed, and the Phase III
trial is being planned. When AlbuBChE was administered to human subjects by
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intramuscular injection, no significant increase in blood pressure was observed, nor was
lethargy reported. The findings indicate that intramuscular administration of AlbuBChE
to humans at the specified dosages (50 to 300 mg per subject) did not result in any
unacceptable side effects and that the specified dosages will allow for the successful
treatment of biological effects of cocaine exposure. Human subjects administrated
AlbuBChE did not report a significant increase in cocaine craving. In contrast, the desire
to use cocaine again and the “overall drug liking” are significantly decreased following
AlbuBChE dosing.19
Another

promising

BChE

mutant

designed

in

our

lab,

i.e.

A199S/F227A/S287G/A328W/Y332G BChE (denoted as E12-7) which has been known
as the most active cocaine hydrolase reported, has a ~2000-fold improved catalytic
efficiency against (-)-cocaine compared to the wild-type BChE, a ~2-fold improved
catalytic efficiency against (-)-cocaine compared to E14-3.61 The in vivo data in a mice
model demonstrated that the minimum effective dose of the enzyme to protect mice from
cocaine-induced lethality (180 mg/kg) is 0.01 mg per mouse (with a weight of ~30
grams).61
To improve the performance of CocE, our lab also designed a series of CocE
mutants. One of the designed CocE mutants, i.e. the T172R/G173Q CocE, has a ~30-fold
improved thermostability (in terms of the in vitro half-life at 37oC) compared to the wildtype CocE and maintains its catalytic activity against cocaine.62 The T172R/G173Q CocE
is currently in Phase II clinical trial.
In summary, the rationally designed BChE and CocE mutants have shown their
values in development of anti-cocaine therapeutic agents. This thesis is a brief summary
of our recently accomplished integrated computational-experimental studies that aim to
design and discover new mutants of these enzymes for the purpose of further improving
their in vitro and in vivo profiles concerning the catalytic activity against (-)-cocaine,
thermostability, and biological half-life. To rationally design desirable mutants of the
enzymes, we have successfully developed computational models, including those for the
BChE gating structure, glycosylated BChE structure, BChE-substrate complex structures,
BChE dimer/tetramer structures, CocE monomer/dimer structures, and CocE-substrate
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complex structures. Development of the computational models enabled us to rationally
design new amino-acid mutations that may improve the catalytic activity, thermostability,
and/or biological half-life. The computational design was followed by wet experimental
tests, including both in vitro and in vivo experiments, leading to discovery of new enzyme
forms with not only a high catalytic efficiency against cocaine, but also an improved
thermostability and prolonged biological half-life. In addition, it has been demonstrated
that a PEGylated CocE mutant can be used to fully protect mice from a lethal dose of
cocaine (180 mg/kg, LD100) for at least three days. The identified new mutants of BChE
and CocE are expected to be valuable candidates for development of a more efficient
enzyme therapy for cocaine abuse. In addition, the encouraging outcomes of the present
study

suggest

that

the

structure-and-mechanism-based

design

and

integrated

computational-experimental approach is reliable for rational protein drug design and
discovery.

Copyright @ Lei Fang 2013
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Chapter Two: Active-Site Gating and Substrate Specificity of Human
Butyrylcholinesterase and Acetylcholinesterase

To design BChE mutants with improved catalytic efficiency against naturally
occurring, biologically active (-)-cocaine, it is necessary to understand the detailed
structure and catalytic mechanism of the enzyme. The general catalytic mechanism of
BChE hydrolyzing (-)-cocaine has been described in previous reports from our
group.61,63,64 In this chapter, the active-site gating mechanism will be described as it is
very important in understanding how substrates can enter the active site and how the
hydrolysis products can leave the active site of the enzyme.65 Further, human BChE and
human acetylcholinesterase (AChE) are highly homologous proteins with distinct
substrate preferences. To gain more structural information about BChE, the active-site
gating and substrate specificity of monomers and tetramers of BChE and AChE were also
compared after performing molecular dynamics (MD) simulations on the enzymes
solvated in water.

2.1 Overview of the active-site gating
Butyrylcholinesterase (BChE) and acetylcholinesterase (AChE) are two
cholinesterases distinguished by their substrate preferences.66 AChE is considered to be
specific to its natural substrate acetylcholine (ACh).67 By rapidly catalyzing the
hydrolysis of ACh, this enzyme is responsible for the termination of cholinergic
neurotransmission at neuronal and neuromuscular synapses.68-70 AChE was found to exist
in multiple forms.71,72 So far, X-ray crystal structures of the catalytic domains of different
species have been identified. These include human AChE (hAChE),73 mouse AChE
(mAChE),74 and Torpedo California AChE (TcAChE).75 Previous studies have shown
that the catalytic domains of AChE in various species overlap with each other well.73
Identical dimers have been observed among different species of AChE with two oppositepositioned subunits associating with each other to form a four helix bundle,73,76 causing
the active sites of the two subunits to face in opposite directions. Recently, the model of
12

an AChE tetramer complexed with collagen-tail protein (ColQ) was built by docking of
the tetramerization domain of an AChE tetramer on the catalytic domains of the
Electrophorus electricus AChE (EeAChE) tetramer.72 Kinetic data have shown that
AChE is one of the most efficient enzymes, with its catalytic efficiency almost reaching
the diffusion limit.69 However, crystal structures of AChE indicate that the active site of
this enzyme is buried at the bottom of a deep and narrow gorge lined with a few aromatic
residues.73-75 Many studies have been reported to search for the cause for the high
catalytic efficiency.69,77-87 The most likely cause is that there may be some alternative
doors in addition to the main door that lead to the active site. These alternative doors can
be channels for small molecules such as water and ions, so that the entering of the
reactants and the leaving of products can be much smoother. So far, three alternative
doors have been proposed, including the back door, the side door, and the acyl loop door.
The back door was first proposed by Sussman et al.78 in 1993 and supported by a short
MD simulation (119 ps) done by McCammon et al.79 in 1994. Later, it was also
supported by longer MD simulations.81-84 This back door is basically formed by four
residues, including Trp86, Gly448, Tyr449, and Ile451 (hAChE residue numbering). The
gating mechanism is described as the temporary side chain (indole ring) movement of
Trp86. Later in 1997, a side door was found by McCammon et al.69,77 using the same
method. This side door is mainly formed by six residues, including Asp74, Thr75, Leu76,
Thr83, Glu84, and Asn87. The gating mechanism of this door was also mainly due to the
fluctuations of the side chains of these residues. Based on previous studies, this side door
was only found in the AChE complex, either with small molecule or with protein. As
explained in one of the studies done by McCammon et al.,81 the substrate here may help
to induce the structural change of the residues that form the side door. In 1998, another
alternative door was proposed by Brooks et al.86 The method they used is different from
the method used by McCammon et al.79 In the paper, they studied two MD trajectories by
using the umbrella sampling method.88 They found this door formed by residues Arg247,
Phe297, and Trp236 could be a better exit for the acetic acid and acetate ion releasing
from AChE. No further information (such as the size and open frequency of this door)
has been released on this door in AChE. But a study on BChE in 2005 found evidence for
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the existence of an analogous door and investigated the size of the door, although the size
of the door is very small, with the average radius of 0.8 ± 0.2 Å during the whole
simulation time.85
Compared with AChE, the natural function of BChE is unclear;23 however, it has
been shown that this enzyme is the principal cocaine hydrolase in human plasma. Thus,
this enzyme could be a promising option to solve the problems of cocaine abuse as we
mentioned in Chapter One. High-activity mutants of this enzyme have become promising
drug candidates for cocaine abuse, considering their powerful effects of protecting
rodents from cocaine toxicity. The first crystal structure of the catalytic domain of human
BChE (hBChE) monomer was identified by Nachon et al.66,47 Studies have shown that
the predominant form of native BChE in plasma is the tetramer.55,89 A model of hBChE
tetramer complexed with a proline-rich peptide was built by our group recently, based on
homology modeling of the AChE tetramer followed by MD simulation of the explicit
water solvated system.90 In comparison with the high selectivity of AChE, BChE was
once called “nonspecific cholinesterase” due to its wide range of substrates, including
acetylcholine, butyrylcholine, succinylcholine, organophosphates, and cocaine.67 In the
study described in this chapter, we compared the main door and alternative doors of the
monomers (AChE and BChE) as well as the main door of the tetramers (AChE and BChE)
by using MD simulations.65 The gating residues of BChE and AChE are found to be
responsible for their distinct substrate specificities. The simulations of the tetramers of
AChE and BChE indicate that although there are some structural differences, the two
active sites of both enzymes facing to the dimer-dimer interface may not function due to
their restricted accessibility to substrates.

2.2 Computational methods used to understand the active-site gating
2.2.1 Molecular dynamics simulations of BChE and AChE
Our computational modeling and simulations started from available X-ray crystal
structures. The X-ray crystal structures of the hAChE and hBChE monomers were from
the Protein Data Bank (PDB ID: 1B4191 and 1P0M92, respectively). The structure of
ColQ of [AChE]4-ColQ (PDB ID: 1VZJ93) was truncated to the proline-rich attachment
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domain (PRAD) consisting of the N-terminal 17 residues to improve the simulation
efficiency. Thus, the AChE tetramer (PDB ID: 1C2O94) complexed with PRAD sequence
is denoted as [AChE]4-PRAD in this chapter. The initial structure of hBChE tetramer
with proline-rich peptide CCLLMPPPPPLFPPPFF (denoted as [BChE]4-PRAD) was
built by our group based on the homology modeling of [AChE]4-ColQ.90
The general procedure for carrying out the MD simulations is similar to that used
in section 2.2 of chapter 2. Briefly, all energy minimizations and MD simulations were
carried out by using the AMBER 9 program package. The Amber force field (ff03) was
used to establish the force field of the protein. A counter ion (Na+) was used to neutralize
the system and, then, the system was immersed in an orthorhombic box of TIP3P water
molecules with a minimum solute-wall distance of 10 Å.95 The whole system was
carefully equilibrated and fully energy-minimized. After that, the system was gradually
heated in the NPT ensemble from 10 K to 300 K over 60 ps. Then, MD simulation was
performed for 10 ns under the normally adopted temperature (300 K). During the MD
simulation, Particle Mesh Ewald (PME) method was employed to deal with the longrange electrostatic interactions.96 The SHAKE procedure was employed to constrain the
lengths of all covalent bonds involving hydrogen atoms,97 with a time step of 2.0 fs. The
atomic coordinates were saved every 1 ps for subsequent sampling and analysis.

2.2.2 Evaluation of the door size
To measure the radii of different doors of AChE and BChE, the MSMS program 98
was employed here in a way similar to how the method has been used elsewhere.69,79,80
Essentially, the MSMS program generates a continuous Connolly surface99 of the protein
by using a probe as shown in Figure 2.1. The shape of each door is approximately treated
as a circle, using radius to describe its size.69,79,80 If the radius of the door is bigger than
the radius of the current probe, then this probe can enter the door and generate the surface
of the gorge which will also be part of the continuous Connolly surface of the protein, as
in Figure 2.1 (A); otherwise, the probe cannot enter the gorge through the door and no
Connolly surface will be generated, as in Figure 2.1 (B). Thus, we can use probes with
different radii to detect the radii of different doors including the main door and the
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alternative ones. To precisely measure the radius, a series of artificial dummy atoms were
used to block the doors other than the one currently being measured. Here we chose
several residues as the probing targets, including Gly122, Glu202, and Ser203 (hAChE
residue numbering). If any of these residues appear in the Connolly surface, that suggests
they have a direct contact with the probe; otherwise their Connolly surface area value
would be zero.

Figure 2.1 The continuous Connolly surface of a protein under different probe radii. (A)
Probe with smaller radius can enter the cave. (B) Probe with a larger radius cannot enter
the cave.

2.3 Stability of the MD trajectories
To explore dynamic stability of the models, the time-dependent root-mean-square
deviation (RMSD) of the atomic positions of the key atoms from their initial positions
were evaluated here. Depicted in Figures 2.2 and 2.3 are the RMSD values of the protein
backbone of BChE/AChE monomer and tetramer, respectively.
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Figure 2.2 Time-dependent RMSD values for the atomic positions of the protein
backbone in the MD-simulated enzyme structures. (A) AChE monomer, and (B) BChE
monomer.

As illustrated in Figures 2.2 and 2.3, all the trajectories start to enter the relatively
stable production phase after 2 ns of MD simulation. The RMSD values are all between
the ranges of 1.0 Å to 2.5 Å during the entire simulation time. Based on the RMSD
values of these trajectories, snapshots after the 2-ns MD simulation can be extracted for
later analysis. Considering the large size of AChE tetramer and BChE tetramer, only the
catalytic domain of each subunit (without tetramerization domain) was analyzed here.
The stable MD trajectories depicted in Figure 2.3 suggest that the tetramer structures of
the enzymes were stabilized during the simulations.
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Figure 2.3 Time-dependent RMSD values for the atomic positions of the protein
backbone in the MD-simulated enzyme structures. (A) AChE tetramer, and (B) BChE
tetramer. Only catalytic domains were calculated here.

2.4 Active-site doors of AChE and BChE monomers
To search for all the possible doors of each enzyme, the structures extracted from
the MD simulation were analyzed. According to the results, there are some similarities
and some differences compared with previous studies. In the study presented in this
chapter, all the aforementioned doors (main door, side door, back door, and acy loop back
18

door) were found to exist, although the size of the acyl loop back door was relatively
smaller. In previous work, two species of AChE (TcAChE and mAChE) were studied.
The hAChE had not previously been examined. Regarding BChE, hBChE is the only
species that has been studied.85 But considering that many X-ray crystal structures have
been determined and different initial structures may cause different results, another X-ray
crystal structure with the PDB ID of 1P0M, which is used by our group for molecular
mechanics (MM) and hybrid quantum mechanics/molecular mechanics (QM/MM)
calculations, was considered. For the monomers, we tried to calculate all the possible
doors; for the tetramers, we focused on the main doors.
Figure 2.4 depicts the main entrance radius values of AChE monomer and BChE
monomer during the MD simulations. The average radius of the main door of AChE
monomer are 1.26 Å with the maximum radius of 2.30 Å as shown in Table 2.1. During
the last 4 ns of the MD simulations, the average radius was 1.51 Å. The entrance radius
seldom reached the maximum value. This result suggested that during the 10-ns MD
simulation, the main door of AChE did not open spontaneously to allow even small
substrates, such as acetylcholine (ACh), to enter the active site. This result was similar to
that reported by McCammon et al. in which the average radius was 1.52 Å with the
maximum radius of 2.40 Å.82 As they concluded, this maximum radius may not be big
enough for even small substrates to enter the active site easily, whereas it was also not
likely to hinder its binding (within the active site) significantly. It has the “dynamic
selectivity” that can prevent the main door from binding much bigger substrates such as
cocaine.83 Figure 2.4 (B) shows the main entrance radius values of the BChE monomer.
The range of the radius was from 1.20 Å to 4.00 Å, which was larger than that of the
AChE. The average entrance radius of the main door was 2.75 Å with the maximum
radius of 4.00 Å. Compared with the “dynamic selectivity” of AChE, BChE can bind not
only small substrates such as ACh, but also large substrates such as cocaine. These data
were also close to the results calculated by Suárez et al. (average radius of 3.1 Å and
maximum radius of 3.8 Å).85
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Figure 2.4 The main-door radii of the monomers: (A, top) AChE; (B, bottom) BChE.

Table 2.1 The average and maximum radii of different doors in monomers.

AChE
Monomer
BChEMo
nomer

Door
main
back
side
acyl loop

Average Radius (Å)
1.26 ±0.2
<1.20
<1.20
<1.20

Maximum Radius (Å)
2.30
1.80
2.10
1.50

main
back
side
acyl loop

2.75±0.3
1.63±0.2
1.69±0.2
<1.20
20

4.00
2.30
2.30
1.70

The difference between the two enzymes can be explained by the different
structures around the main entrance area. In AChE, according to the MD simulation,
there are eight aromatic residues associated with the main door. Three of them are located
on the entrance of the active site (Tyr72, Trp286, and Tyr341); five of them are located
almost the same depth inside the gorge (Tyr124, Phe295, Phe297, Tyr337, and Phe338),
as show in Figure 2.5 (A). In BChE, however, six of these residues are changed to
smaller ones, including Tyr72 to Asn68, Tyr124 to Gln119, Trp286 to Ala277, Phe295 to
Leu286, Phe297 to Val288, and Tyr337 to Ala328, with both sets of residues shown in
Figure 2.5 (B) and (C). These smaller residues may significantly enlarge the entrance
radius, which makes it possible for substrates as large as cocaine to enter the active site.
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Figure 2.5 (A, upper) The eight residues with aromatic or indole side chains in the gorge
of AChE. (B, middle) The eight residues in the gorge of BChE. (C, bottom)
Superimposing of the gating residues in AChE and BChE.
22

For the monomers, we also analyzed the alternative doors suggested in previous
studies. In this study, all these alternative doors were found and shown in Figures 2.6 and
2.7. The average radii of these three doors in AChE are all below 1.20 Å, but with
different maximum radii and different fractions of opening snapshots (values larger than
1.40 Å will be considered as open, the approximate radius of a water molecule). A small
fraction (139 out of 8000) of the sampling snapshots showed the opening of the back
door. This finding is consistent with a previous study in which 78 out of 10000 snapshots
showed the back-door opening event.82 The flip of the indole ring of Trp 82 is believed to
be responsible for this opening. In the current study, the side door has a longer opening
time; 3463 out of 8000 sampling snapshots showed the open state. The fluctuations of the
side chains of residues that form the side door are responsible for the opening.
After the acyl loop back door was first suggested in 1998 by Brooks et al.,86 no
further studies had been reported to examine this door in AChE before our analysis of the
door in the study described in this chapter. According to the analysis, 77 out of the 8000
snapshots were associated with the opening of acyl loop back door with the maximum
value of 1.50 Å. This was the first time that the existence and the size of the acyl loop
back door of AChE were observed and detected by performing MD simulation and the
Connolly Surface analysis, although the observed opening snapshots were few and the
size of the door was small.
In BChE, the characteristics of these three alternative doors have some similarities
but also some differences compared with those of AChE. The calculated average radius
of the back door is 1.63 Å with the maximum radius of 2.30 Å. The average radius of the
side door is 1.69 Å with the maximum radius of 2.30 Å. The calculated values of the radii
are systematically larger than the corresponding values calculated previously by Suárez et
al.,85 who reported an average radius of 0.8 Å with a maximum radius of 1.2 Å for the
back door and an average radius of 1.1 Å with a maximum radius of 2.2 Å for the side
door. One of the possible reasons might be associated with the different versions of the
Amber force field. The ff03 was used in this MD simulation with Amber 9 program,
whereas the specific Amber force field version used for their MD simulation85 with
Amber 7 was not specified.
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The acyl loop back door in BChE was also observed in this study. As in AChE,
the calculated average radius for the acyl loop back door is smaller than 1.20 Å. The
snapshots with the door opening (defined as the radius being larger than 1.4 Å) are even
fewer in BChE. 77 snapshots (out of 8000) show the opening event in AChE, whereas
only 9 snapshots (out of 8000) showed the opening event in BChE. In the MD simulation
reported previously by Suárez et al.,85 no opening event was observed. All of the
computational results suggest that the acyl loop back door in BChE may be insignificant
for its catalytic function. Overall, for both AChE and BChE, the acyl loop back door is
not as important as the other doors.
To summarize the results calculated for the monomers, there are some similarities
but also some differences between the AChE and BChE monomers. BChE has a larger
main entrance than AChE, which seems reasonable as BChE can bind substrates as large
as cocaine. Two alternative doors (side door and back door) in BChE are larger in size
than in AChE. The acyl loop back doors in both enzymes are too small to be significant
channels leading to the active sites. Based on these results, it is believed that the back
door and the side door are more likely and more important alternative doors than the acyl
loop back door, as the former ones have larger radii and can exist for longer time. As
discussed in a previous study,80 there is still no direct experimental evidence to prove the
function of these alternative doors. However, multiple simulations done by different
groups using different forms of enzymes and different force fields have all predicted the
existence of these doors (see Figures 2.6 and 2.7 for these alternative doors).
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Figure 2.6 The overall and detailed view of different entrances to the active site of AChE.
The blue grid means the Connolly surface. The red arrows point from outside of the
protein Connolly surface to the inside of active site in (B), (C), (D), and (E). The residues
that form the entrances are showed in different color: main door in orange, side door in
cyan, back door in yellow, acyl loop door in green, the active site in purple. (A) All doors,
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the red arrows point the location of different doors. (B) The main door. (C) The side door.
(D) The back door. (E) The acyl loop door.

Figure 2.7 The overall and detailed view of different entrances to the active site of BChE.
The blue grid means the Connolly Surface. The red arrows point from outside of the
protein Connolly surface to the inside of active site in (B), (C), (D), and (E). The residues
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that form the entrances are showed in different color: main door in orange, side door in
cyan, back door in yellow, acyl loop door in green, the active site in purple. (A) All doors,
the red arrows point the location of different doors. (B) The main door. (C) The side door.
(D) The back door. (E) The acyl loop door.
2.5 Active-site doors of AChE and BChE tetramers
Since AChE can exist in the forms of dimer and tetramer and the dominant form
of native hBChE in plasma is the tetramer, MD simulations were performed to simulate
both [AChE]4-PRAD and [BChE]4-PRAD. For the tetramer systems, we mainly focused
on the main doors. The overall structures of [AChE]4-PRAD and [BChE]4-PRAD were
similar, as shown in Figure 2.8. The parts inside the red squares as labeled in Figure 2.8
(A) and (B) indicated the tetramerization domains, while the others were the catalytic
domains of the two enzymes. The four subunits of each enzyme were labeled in four
different colors. The tetramers were dimers of the dimers with each dimer oriented
vertically. As mentioned in a previous paper,90 the two dimers were oriented in an antiparallel pattern, so that the subunits of the tetramers are diagonally equivalent. As shown
in Figure 2.8 (A) and (B), the two active sites labeled with triangles were fully exposed to
the solvent; the other two active sites labeled with circles faced to the interface between
two dimers (labeled with rectangles).

27

Figure 2.8 The overall view of AChE tetramer and BChE tetramer. Different subunits are
shown clockwise in different colors: subunit A in orange, subunit B in cyan, subunit C in
green, and subunit D in blue. Also, the active sites are shown in purple and the prolinerich peptide is shown in red. The red circles show the location of the active sites that are
exposed to solvent in each monomer. The triangles show the location of the active sites
that face to the interface between two dimers (shown by the rectangle). The squares in the
middle show the location of tetramerization domain in each tetramer. Subunit A and
subunit B forms one dimer, while subunit C and subunit D forms the other dimer.

The data summarized in Table 2.2 indicate that for the AChE tetramer, the
average radii of the main door of each subunit are 1.67 Å, 0.85 Å, 1.65 Å, and 0.80 Å,
with the maximum radii of 2.40 Å, 1.30 Å, 2.30 Å, and 1.20 Å, respectively. In the BChE
tetramer, these values are 2.07 Å, 1.24 Å, 2.30 Å, and 1.63 Å, with the maximum radii of
3.70 Å, 2.60 Å, 3.40 Å, and 2.80 Å, respectively. In both enzymes, two active sites facing
the solvent have a better chance of binding the substrates compared with the two active
sites facing to the dimer-dimer interface, which can be seen in Figures 2.8 and 2.9. Figure
2.9 (A) shows that if the main doors of the enzyme (subunits A and C) that facing to the
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solvent are opened wide enough, then substrates such as ACh could enter it by following
the direction indicated by the white arrow. However, for the subunits B and D (the left
part, labeled in multiple colors in Figure 2.9 (B) to (D)) of these two tetramers, the
probability of finding a path that can lead to the active site in subunit B/D without being
blocked by subunit A/C would be very low, if not impossible. The conformational
flexibility of ACh was considered in this analysis. Illustrated in Figure 2.9 (B) to (D) are
representative scenarios in which ACh entering the active site of subunit B/D (left part,
labeled in multiple colors) is blocked by subunit A/C (the right part, labeled in green).

Table 2.2 The average and maximum radii of main doors in tetramers
Door
main (subunit A)

Average Radius (Å)
1.67 ±0.3

Maximum Radius (Å)
2.40

AChE

main (subunit B)

0.87 ±0.1

1.30

Tetramer

main (subunit C)

1.65 ±0.2

2.30

main (subunit D)

0.80 ±0.1

<1.20

main (subunit A)

2.07 ±0.3

3.70

BChE

main (subunit B)

1.24 ±0.1

2.60

Tetramer

main (subunit C)

2.30 ±0.2

3.40

main (subunit D)

1.63 ±0.2

2.80
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Figure 2.9 (A) Acetylcholine (ACh) can enter the active site of AChE/BChE monomer or
AChE/BChE tetramer subunits A and C when the main door is open. The white arrow
shows the entering direction. (B) to (D) The path to active site of AChE/BChE tetramer
subunit B or D (left part, labeled in multiple colors) is blocked by subunit A or C (right
part, labeled in green). The white crosses mean the clash between ACh and the subunits.
Subunits A and D form one dimer, whereas subunits B and C form the other dimer, in the
tetramer. The figure was drawn based on the simulated BChE tetramer structures.

Further, in order to identify the specific residues in subunit A/C of AChE/BChE
tetramer that block ACh entering the active site of the complementary subunit B/D, the
distances between the key residues on the main door of subunit B/D and the nearby
residues of the complementary subunit A/C in the simulated tetramer structures of AChE
and BChE were examined carefully. For convenience of discussion, here it was focused
on the inter-residue distances between three representative residues on the entrance of the
main door in subunit B and residues in complementary subunit A. The three
representative residues of AChE are Tyr72, Trp286, and Tyr341, whereas the
corresponding residues of BChE are Asn68, Ala277, and Tyr332. The inter-residue
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distances between subunits C and D are similar to the corresponding inter-residue
distances between subunits A and B. For each snapshot of the MD-simulated tetramer
structure, we evaluated the distance between the center of mass of each representative
residue in subunit B and that of each residue in complementary subunit A. According to
the calculated distances, for AChE, the residues in subunit A that are the closet to Tyr 72,
Trp 286, and Tyr 341 in subunit B are Asp320, Phe321, Gln322, and Gln420. The
corresponding residues in subunit A of BChE are Leu309, Gly310, Gln311, and Trp412.
The calculated inter-residue distances involving these residues of BChE are depicted in
Figure 2.10; the plots for the corresponding inter-residue distances in AChE (data not
shown) are similar to the results obtained for BChE. The inter-residue distances
calculated for the snapshots between 2000 and 10000 ps are used to determine the
average inter-residue distance for each pair of residues. The determined average interresidue distances are summarized in Table 2.3.

Table 2.3 The inter-residue distances (RAB, in Å) between the center of mass of
representative residues in subunit B and that of the main blocking residues in
complementary subunit A of AChE and BChE tetramers.
Distancea in the AChE tetramer

Distancea in the BChE tetramer

Tyr72B Trp286B Tyr341B
Asn68B Ala277B
Tyr332B
17.50
12.72
17.28
15.73
9.77
17.70
Asp320A
Leu309A
(7.02)
(2.24)
(6.78)
(6.42)
(4.97)
(7.11)
20.67
16.75
21.00
16.63
12.20
19.63
Phe321A
Gly310A
(8.98)
(5.06)
(9.29)
(8.14)
(4.19)
(9.86)
15.21
14.50
16.94
15.21
11.94
20.70
Gln322A
Gln311A
(4.21)
(3.50)
(5.92)
(5.69)
(2.90)
(9.90)
18.03
15.22
17.96
19.32
15.93
19.56
Gln420A
Trp412A
(7.30)
(4.49)
(7.21)
(8.91)
(6.00)
(7.87)
a
The distance (RAB) between the center of mass of a residue in subunit B and a residue in
complementary subunit A. Given in the parentheses are the corresponding RAB values
(RAB = RAB – RA – RB, where RAB refers to the average inter-residue distance between
residues A and B, and RA and RB are the average vdW radii of residues A and B,
respectively). The RA and RB values used to determine the RAB values are listed in Table
2.4.
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Table 2.4 The calculated average vdW radii (Å) of the residues involved in the interresidue distance calculations for residues in subunits A and B of the AChE and BChE
tetramers.

a

AChE
Asp320A
Phe321A
Gln322A

vdW radiusa
4.54
5.75
5.06

BChE
Leu309A
Gly310A
Gln311A

vdW radiusa
4.80
3.98
5.01

Gln420A

4.79

Trp412A

5.90

Tyr72B
5.94
Asn68B
4.51
Trp286B
5.94
Ala277B
4.03
Tyr341B
5.96
Tyr332B
5.79
The vdW radius of a residue is defined as the longest distance between the center of

mass of the residue and the vdW surface of the residue. The vdW radius calculations
were based on the MD trajectories between 2000 and 10000 ps.
The van der Waals (vdW) radius of each residue involved in the inter-residue
distance calculations were calculated here, and the average vdW radius for the snapshots
between 2000 and 10000 ps were determined. The determined average vdW radii are
summarized in Table 2.4. Based on the calculated average inter-residue distances and
average vdW radii, another type of distance (which may be called effective inter-residue
distance) was evaluated, denoted by RAB:
RAB = RAB – RA – RB

(1)

in which RAB refers to the average inter-residue distance between residues A and B,
whereas RA and RB are the average vdW radii of residues A and B, respectively. The
RAB values, that are also summarized in Table 2.3 (the values in parentheses), are a
better indicator concerning how close the two residues are to each other.
As seen from the RAB values summarized in Table 2.3, the smallest RAB value
is ~2.9 Å between Ala277 in subunit B and Gln311 in subunit A for the BChE tetramer
(see Figure 2.10 (E)). The other two residues (Leu309 and Gly310) in subunit A are also
close to Ala277 in subunit B. So, the entrance of the main door in subunit B of the BChE
tetramer is blocked mainly by Leu309, Gly310, and Gln311 residues in complementary
subunit A, while Trp412 had only a minor role in the blocking.
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For the AChE tetramer, the smallest RAB value is ~2.2 Å between Trp286 in
subunit B and Asp320 in subunit A. The other three residues (Phe321, Gln322, and
Gln420) in subunit A are also close to Trp286 etc. in subunit B. So, the entrance of the
main door in subunit B of the AChE tetramer is blocked mainly by Asp320, Phe321,
Gln322, and Gln420 residues in complementary subunit A.
To summarize the results obtained from the comparison between the AChE and
BChE tetramers, although there are some differences in the size and shape of the active
site cavities of the two tetramers, they share some similarity. Two active sites that face
the solvent can be the functional active sites, while the other two are not. Considering the
door size and the restricted route a substrate could go through to get close to the active
site gorge, the possibility of the substrates entering the two interface-facing active sites of
both enzymes could be significantly decreased. This observation is also supported by
previous experimental studies showing that a possible AChE tetramer with molecular
weight of 250 kDa had two effective active sites per molecule.100
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A

B

C

D

E
Tyr322B

Trp412A

Leu309A
Ala277B

Gly310A

Asn68B

Gln311A

Figure 2.10 (A) – (D) Time-dependence of the key inter-residue distances between the
center of mass of representative residues in subunit B and that of the main blocking
residues in complementary subunit A in the MD-simulated BChE tetramer. (E) A
snapshot of the MD-simulated BChE tetramer, showing the relative positions of the
residues involved in the inter-residue distance calculations.
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2.6 Conclusion
The active sites and gating mechanisms of AChE and BChE are compared after
performing MD simulations on the water-solvated systems of the monomers and
tetramers of hBChE and AChE. It has been demonstrated that the different gating
mechanisms due to the conformational dynamics of gating residues of AChE and BChE
are responsible for their different substrate specificities. The simulations of the tetramers
of AChE and BChE indicate that although there are some structural differences, both
enzymes could have two dysfunctional active sites due to their special locations.

Copyright @ Lei Fang 2013
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Chapter Three: Substrate Selectivity of High-Activity Mutants of Human
Butyrylcholinesterase

An ideal, therapeutically valuable mutant of human BChE should have not only a
high catalytic activity against (-)-cocaine and long biological half-life in human body, but
also certain selectivity for (-)-cocaine over neurotransmitter acetylcholine (ACh) such
that one would not expect systemic administration of the BChE mutant to interrupt
cholinergic transmission. In this study, enzyme-substrate complex models were built and
simulated to account for the mutation-caused changes of the catalytic activities of BChE
against both (-)-cocaine and ACh. In addition, it is also interesting to know the catalytic
activities of the designed BChE mutants against other known substrates, including
acetylthiocholine (ATC), butyrylthiocholine (BTC), and (+)-cocaine, in comparison with
the corresponding catalytic activity against (-)-cocaine.

3.1 Desirable substrate selectivity of the human BChE mutants
As well known, computational design of high-activity mutants of an enzyme is
extremely challenging, particularly when the chemical reaction process is ratedetermining for the enzymatic reaction.64,101,102 To computationally design a mutant
enzyme with an improved catalytic activity for a given substrate, one needs to design
possible amino-acid mutations that can accelerate the rate-determining step of the
catalytic reaction process while other steps of the reaction are not slowed down by the
mutations. 57,63,103 The fundamental reaction pathway for BChE-catalyzed hydrolysis of ()-cocaine was uncovered in our former studies by extensive molecular dynamics (MD)
simulations57,63 and reaction-coordinate calculations63,103 using quantum mechanics (QM)
and hybrid quantum mechanics/molecular mechanics (QM/MM). The computational
studies revealed that the rate-determining step of (-)-cocaine hydrolysis catalyzed by the
A328W/Y332A and A328W/Y332G mutants of BChE is the first step of the chemical
reaction process.57,58,63,101 Therefore, starting from the A328W/Y332A or A328W/Y332G
mutant, rational design of BChE mutants against (-)-cocaine has been focused on
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decreasing the energy barrier for the first reaction step (depicted in Scheme 3.1) without
significantly affecting the other steps. Our group has developed unique computational
strategies and protocols based on the virtual screening of rate-determining transition
states of the enzymatic reaction to design enzyme mutants with improved catalytic
activity.58-60,104-107 The computational design was then followed by in vitro experiments,
including site-directed mutagenesis, protein expression, and enzyme activity assays, and
in vivo experiments. The integrated computational-experimental studies have led to
discovery of a series of BChE mutants with a significantly improved catalytic efficiency
against (-)-cocaine.58-60,104-108
The study described in this chapter was focused on the substrate selectivity of our
discovered high-activity mutants of human BChE. Computational modeling was carried
out to analyze the catalytic activities of the promising BChE mutants against other known
substrates, including acetylcholine (ACh), acetylthiocholine (ATC), butyrylthiocholine
(BTC), and (+)-cocaine, in comparison with the corresponding catalytic activity against ()-cocaine. In particular, ACh is the only known natural substrate of BChE in the body.
The catalytic activities of wild-type BChE against ACh, ATC, BTC, and (+)-cocaine are
all much higher than that against (-)-cocaine.109-111 So, it is interesting to know whether
the same amino-acid mutations designed to considerably increase the catalytic activity of
BChE against (-)-cocaine also considerably increase the catalytic activities of BChE
against other substrates. According to the simulation results, the computationally
designed mutations only considerably improve the catalytic efficiency of human BChE
against (-)-cocaine, without significantly improving the catalytic activities against other
substrates, which were proven by the obtained kinetic data (to be published elsewhere,
not shown in this thesis).
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Scheme 3.1 The first reaction step of (-)-cocaine hydrolysis catalyzed by a BChE mutant
including the A199S mutation.
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3.2 Computational methods used to assess the substrate selectivity
Various substrates interacting with human BChE and its mutants were modeled
for their enzyme-substrate binding complexes (denoted as ES’s) and transition states for
the initial reaction step (denoted as TS1’s) by using the same modeling strategy and
approach that we used to study (-)-cocaine interacting with the enzymes.58,107,108,112 The
strategy of performing an energy minimization or molecular dynamics (MD) simulation
on a transition state structure of an enzymatic reaction using a classical force field
(molecular mechanics) has been described in section 2.2 of chapter 2. During the energy
minimization or MD simulation on the TS1 structure, the lengths of transition bonds (i.e.
the covalent bonds that are being broken or formed gradually during the initial reaction
step) were restrained while all other geometric parameters were allowed to move. The
transition bond lengths used in the modeling of the TS1 structures for each pair of
enzyme and substrate were based on our previously reported molecular modeling and
reaction-coordinate calculations on BChE-catalyzed hydrolysis of (-)-cocaine or ACh or
ATC.60,113,114 The computational procedures for modeling a TS1 structure were the same
as those for modeling the corresponding ES structure, except for keeping the transition
bond lengths restrained during the energy minimization or MD simulation on the TS1
structure.
The initial structures of BChE and the mutants used in the molecular modeling
were prepared on the basis of our previous MD simulation on the enzyme-substrate
complex for wild-type BChE binding with (-)-cocaine.57,58,107 Our previous MD
simulations on the enzyme-substrate complexes started from the X-ray crystal structure
deposited in the Protein Data Bank (PDB ID: 1P0M).115 The procedure for carrying out
the MD simulations on the enzyme-substrate interactions in water is the same as that
described in section 2.2 of chapter 2.

3.3 Insights from the computational modeling
Molecular modeling enabled us to understand how human BChE and its mutants
interact with ACh, ATC, BTC, (+)-cocaine, and (-)-cocaine in the ES and TS1 structures.
According to the modeling, for (-)-cocaine interacting with wild-type BChE, there is only
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one hydrogen bond (H-bond) between the carbonyl oxygen of (-)-cocaine and the
oxyanion hole (G116, G117, and A199) in the ES structure, and there are two H-bonds in
the

TS1

structure,

as

seen

in

Figure

3.1

(A)

and

(B).

With

the

A199S/F227A/S287G/A328W/Y332G mutant (E12-7), there are two H-bonds between
the carbonyl oxygen of (-)-cocaine and the oxyanion hole (G116, G117, and S199) in the
ES structure and three H-bonds in the TS1 structure, as seen in Figure 3.1 (C) and (D).
The extra H-bond in both the ES and TS1 structures is with the hydroxyl group of S199
after the A199S mutation. The modeled ES and TS1 structures suggest that this mutant
should have a significantly higher catalytic activity against (-)-cocaine compared to the
wild-type BChE.

Figure 3.1 The energy-minimized ES and TS1 structures for (-)-cocaine interacting with
wild-type human BChE and its A199S/F227A/S287G/A328W/Y332G mutant (E12-7).
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For substrate ACh interacting with the wild-type BChE or anyone other mutants,
there are always two H-bonds between the carbonyl oxygen of the substrate and the
oxyanion hole (G116, G117, and A/S199) in the ES structure and three H-bonds in the
TS1 structure. Depicted in Figures 3.2 are the modeled ES and TS1 structures with wildtype BChE and a representative mutant E12-7. Depicted in Figures 3.3 are the modeled
ES

structures

with

A199S/S287G/A328W/Y332G

A199S/F227A/S287G/A328W/E441D

mutant

mutant

(noted

(noted
as

as

E12-4),

E14-3),
and

A199S/F227A/S287G/A328W/Y332G/E441D mutant (noted as E13-1).

Figure 3.2 The energy-minimized ES and TS1 structures for ACh interacting with wildtype human BChE and its A199S/F227A/S287G/A328W/Y332G mutant (E12-7).
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Figure 3.3 The energy-minimized ES structures for ACh interacting with E14-3, E12-4,
and E13-1.
For other substrates (including ATC, BTC, and (+)-cocaine) interacting with the
wild-type BChE or E12-7, there are always two H-bonds between the carbonyl oxygen of
the substrate and the oxyanion hole (G116, G117, and A/S199) in the ES structure and
three H-bonds in the TS1 structure. Depicted in Figures 3.4 to 3.6 are the modeled ES
and TS1 structures with wild-type BChE and E12-7. The hydroxyl group of S199 in the
mutant does not form an extra H-bond in the ES or TS1 structure for the mutant
interacting with any substrate other than (-)-cocaine, suggesting that E12-7 should not
have dramatically improved catalytic activities against ATC, BTC, and (+)-cocaine
compared to the wild-type BChE.
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Figure 3.4 The energy-minimized ES and TS1 structures for ATC interacting with wildtype human BChE and its A199S/F227A/S287G/A328W/Y332G mutant (E12-7).
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Figure 3.5 The energy-minimized ES and TS1 structures for BTC interacting with wildtype human BChE and its A199S/F227A/S287G/A328W/Y332G mutant (E12-7).
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Figure 3.6 The energy-minimized ES and TS1 structures for (+)-cocaine interacting with
wild-type human BChE and its A199S/F227A/S287G/A328W/Y332G mutant (E12-7).

3.4 Experimental validation
The computational insights were validated by experimental kinetic analysis (see
the kinetic parameters summarized in Table 3.1).116 As seen in Table 3.1, the BChE
mutant E12-7 has a 2000-fold improved catalytic efficiency (kcat/KM) against (-)-cocaine.
The same mutations do not dramatically improve the catalytic efficiencies of human
BChE against the other substrates.
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Table 3.1 Kinetic parameters determined for substrate hydrolyses catalyzed by wild-type
human BChE and E12-7. The in vitra activity assays were performed by Shurong Hou,
Liu Xue, and Wenchao Yang in our lab.116

Substrate

Enzyme

KM

kcat
-1

kcat/KM
-1

-1

(µM) (min ) (M min )

RCEa

wild-type BChE

4.5

4.1

9.1 × 105

1

E12-7

3.1

5,700

1.8 × 109

2,020

wild-type BChE

4.7

6,420

1.4 × 109

1

E12-7

4.6

8,990

2.0 × 109

1.43

wild-type BChE

148

61,200

4.1 × 108

1

E12-7

37

11,900

3.2 × 108

0.78

wild-type BChE

33

20,200

6.1 × 108

1

E12-7

20

14,800

7.2 × 108

1.19

wild-type BChE

17

29,500

1.7 × 109

1

E12-7

13

28,000

2.2 × 109

1.24

(-)-cocaine

(+)-cocaine

ACh

ATC

BTC

3.5 Conclusion
In this study, enzyme-substrate complex models were built and simulated to
account for the mutation-caused changes of the catalytic activities of BChE and its
mutants against both (-)-cocaine and other substrates (including acetylcholine,
acetylthiocholine, butyrylthiocholine, and (+)-cocaine). According to the simulation
results, the computationally designed mutations only considerably improve the catalytic
efficiency of human BChE against (-)-cocaine, without significantly improving the
catalytic activities against other substrates. The computational insights have been
confirmed by the experimental kinetic analysis.116
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Chapter Four: Model of Glycosylated Human Butyrylcholinesterase

In order to effectively suppress cocaine reward in the brain for a long period of
time after an exogenous cocaine hydrolase administration, the therapeutic enzyme should
have not only a high catalytic efficiency against cocaine, but also a sufficiently long
circulation time. It has been known that PEGylation modification of a therapeutic protein
can prolong the biological half-life of the protein without affecting its biological function.
However, the asparagine-linked glycans on the surface of glycosylated BChE may
interfere with the PEGylation modification. In the study described in this chapter, we
built a three-dimensional (3D) model of glycosylated human BChE to investigate the
influence of glycans on the PEGylation modification.

4.1 Understanding the detailed structure of a glycosylated protein
To effectively suppress cocaine reward in the brain for a long period of time after
an exogenous cocaine hydrolase administration, the therapeutic enzyme should have not
only a high catalytic efficiency against (-)-cocaine, but also a sufficiently long circulation
time for cocaine addiction treatment. Unfortunately, studies have shown that recombinant
BChE expressed in various expressing systems all have a short biological half-life in
animal models ranging from minutes to hours.117 Success in PEGylation modification of
peptides and proteins would be an ideal option to improve the biological half-life.118
However, as the potential PEGylation sites are always located on the protein surface,
some post-translational modification, such as glycosylation, may interfere with the
PEGylation. So, the nine asparagine-linked glycans on the surface of BChE could
probably hinder the PEGylation modification.119 It is essentially important for rational
design of protein engineering, particularly the PEGylation, to know the three-dimensional
(3D) structure of the glycosylated human BChE.
On the other hand, it is extremely challenging to obtain a single crystal of a
glycosylated protein and determine the crystal structure, particularly for human BChE. In
order to prepare a single crystal of human BChE, one had to make certain mutations on
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the glycosylation sites.92 Hence, available X-ray crystal structures of human BChE or its
mutant do not include all structural information about the glycans of the native protein.120
In the study described in this chapter, a 3D model of the glycosylated human
BChE starting from the available X-ray crystal structure of the unglycosylated BChE was
modeled and simulated. According to the simulated results, glycans did not change the
overall stability of the BChE structure, but could increase the flexibility of some local
structures. The Solvent Accessible Surface Area (SASA) analysis revealed that some
lysine residues have a significant decrease in SASA due to direct or indirect effects of
their surrounding glycans. The modeling and simulation provide valuable insights
concerning how the glycans affect the BChE structure and how the glycans influence the
PEGylation modification of BChE. These insights will be useful in guiding future
rational design of BChE engineering.

4.2 Computational methods used to study the structure of glycosylated BChE
4.2.1 Construction of the glycosylated BChE model
Our computational modeling the glycosylated human BChE structure started from
the unglycosylated BChE structure discussed in chapters 2 and 3. The starting
(unglycosylated) BChE structure was taken from the X-ray crystal structure deposited in
Protein Data Bank at 2.0 Å resolution (PDB ID: 1P0M).92 A few modifications were
made to fix this structure. First, all small molecules and the carbohydrate chains were
removed, except the crystal waters. Second, the missing residues (Asp2, Asp3, Asp378,
Asp379, and Gln455) were added manually by TLEAP module in Amber 9 package.121
Further, the mutated residues Gln17, Gln455, Gln481, and Gln486 were changed back to
Asn17, Asn455, Asn481, and Asn486, respectively. Finally, the protonation states of
histidine residues were modified after manually inspecting their local environments.
His126, His214, His372, and His438 were protonated on their Nδ atoms, whereas His77,
His207, and His423 were protonated on their Nε atoms. This initial structure was then
optimized using the SANDER module of the Amber 9 package121,122 for constructing the
glycosylated BChE model.
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The initial model of the glycosylated human BChE was constructed based on the
above optimized BChE structure using the Glycam Biomolecule Builder.123 Nine
biantennary glycans are located on the surface of BChE. Each glycan is covalently linked
to the Nδ atom of asparagine (Asn17, Asn57, Asn106, Asn241, Asn256, Asn341, Asn451,
Asn481, and Asn486).119 Each of the simulated glycans was composed of 11
carbohydrate residues (see Figure 4.1), according to the experimental results based on
serum human BChE from Kolarich et al.124 For convenience, the nine glycans are named
in accordance with their linkage residue number, i.e. Glycan17, Glycan57, Glycan106,
Glycan241, Glycan256, Glycan341, Glycan451, Glycan481, and Glycan486.

Figure 4.1 The composition of the glycan in human BChE.
4.2.2 Molecular dynamic simulations
The procedure for carrying out the molecular dynamic (MD) simulations is
similar to that used section 2.2 of chapter 2. Briefly, all energy minimizations and MD
simulations were carried out by using the AMBER 9 program package. The Amber force
field (ff03) was used to establish the potentials of protein,125 and Glycam06 force field
was used to establish the potentials of glycans.126
The initial model of the glycosylated human BChE was built based on the fully
energy-minimized BChE structure and, then, was further carefully equilibrated via MD
simulation and energy-minimized again at the end. The same procedure used to simulate
the unglycosylated human BChE structure was employed to simulate the glycosylated
human BChE structure for 10 ns.

4.3 Structural features of the glycosylated BChE
Through molecular modeling and MD simulations, a dynamically stable 3D
model of the glycosylated human BChE in comparison with that of the unglycosylated
human BChE was obtained. To explore dynamic stability of the models, the timedependent root-mean-square deviation (RMSD) of the atomic positions of the key atoms
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from their initial positions was evaluated. Depicted in Figure 4.2 are the RMSD values of
the protein backbone and the heavy atoms of glycans. As seen in Figure 4.2 (A), the
RMSD values for the protein backbone in both models (i.e. the unglycosylated and
glycosylated human BChE structures) reached the equilibrium after 1 ns during the MD
simulations and kept stable in the remaining time of the simulations. The average RMSD
value of the backbone of the unglycosylated BChE during the stable stage was 1.26 Å
which is close to that of the glycosylated BChE, 1.24 Å, suggesting that the dynamic
stability of BChE at room temperature was not changed significantly by the glycans.
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Figure 4.2 Time-dependent RMSD values for the atomic positions of the protein
backbone and glycan backbone in the MD-simulated unglycosylated and glycosylated
human BChE structures. (A) BChE (red) and Glycosylated BChE (black); (B) Glycan17
(black), Glycan57 (red), Glycan106 (green), Glycan241 (blue), and Glycan256 (pink); (C)
Glycan341 (black), Glycan455 (red), Glycan481 (green), and Glycan486 (blue).

As seen in Figures 4.2 (B) and (C), after 1 ns of the MD simulation, the RMSD
values for the heavy atoms of the glycans all reached the dynamically equilibrium stage,
with the RMSD values fluctuating between ~2 and ~6 Å. The average RMSD values of
the heavy atoms of Glycan17, Glycan57, Glycan106, Glycan241, Glycan256, Glycan341,
Glycan455, Glycan481, and Glycan486 were 3.37 Å, 4.65 Å, 4.38 Å, 3.52 Å, 3.55 Å,
4.09 Å, 3.79 Å, 4.33 Å, and 4.32 Å, respectively.
Depicted in Figure 4.3 is the MD-simulated structure (the last snapshot) of the
glycosylated BChE. Nine glycans are located on the surface of the enzyme. If α-helix
where residue Ser198 is located can be viewed as a virtual central axis of the protein,
50

there are more glycans (Glycan17, Glycan57, Glycan106, Glycan241, Glycan455,
Glycan481, and Glycan486) on the left side of the protein than the right side (Glycan241,
Glycan256, and Glycan341). In addition, glycans are all far away from the active-site
entrance of the enzyme. Hence, the glycosylation should have no significant influence on
the catalytic function of human BChE.

Figure 4.3 Overall structure of the glycosylated human BChE model derived from the
MD simulation. The orange ribbons represent BChE, and the blue sticks refer to the nine
glycans. The cyan sticks represent the nine linkage asparagine residues. The red ribbon
refers to the α-helix where Ser198 is located.

It is interesting to know the potential hydrogen bonding between the glycans and
BChE itself. Hence, hydrogen bond analysis was performed using PTRAJ module in
AMBER 9 package based on the sampling snapshots (once every 20 ps after 1 ns) from
the MD simulation. The hydrogen bond analysis was based on a simple criterion that the
distance between the hydrogen and the hydrogen-bond acceptor (oxygen or nitrogen) was
shorter than 3.0 Å. Hydrogen bonds were counted according to their overall appearance
time during the simulation. For example, if a hydrogen bond existed in 50% of the
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collected snapshots, it was counted as half (0.5) of a hydrogen bond. According to the
results, there were only 1.7 hydrogen bonds in average formed between each glycan and
the BChE protein during the MD simulation, suggesting that the hydrogen bonding
between the glycans and the BChE protein is moderate.

4.4 Solvent Accessible Surface Area (SASA)
It has been known that PEGylation can significantly prolong the biological halflife of a therapeutic protein without affecting its biological functions. BChE can be
PEGylated through lysine linkage chemistry, as there are lysine residues on the BChE
surface. However, asparagine-linked glycans on the surface of glycosylated BChE may
interfere with the PEGylation modification of the enzyme. In the study described in this
chapter, we tried to evaluate the influence of the steric hindrance of glycans on the
potential PEGylation reaction sites, specifically the Nε atoms of lysine residues. To
achieve this, the SASA values of the Nε atoms of all the 31 lysine residues on the enzyme
surface were calculated and analyzed by using the MSMS program127 for both the
unglycosylated and glycosylated BChE models. Three probes with different radii were
chosen to represent the approximate sizes of different functional groups of different
PEGylation reagents.128 A probe with a radius of 1.4 Å represents a small functional
group, such as carbonyl group. A probe with a radius of 4 Å represents a medium
functional group, such as epoxide group. A probe with a radius of 8 Å represents a large
functional group, such as benzotriazole group (see Figure 4.4).

Figure 4.4 Representative PEGylation reactions.
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The relative SASA values of the Nε atoms of lysine residues calculated using
different probe radii in the unglycosylated and glycosylated BChE models are listed in
Table 4.1. In the unglycosylated BChE, the relative SASA values of the Nε atoms
calculated using the radii of 1.4, 4, and 8 Å range from 4.79% to 45.99%, 0.01% to
25.83%, and 0.0% to 16.97% with the average values of 30.12%, 11.34%, and 5.77%,
respectively. In the glycosylated BChE model, the relative SASA values of the Nε atoms
of lysine residues calculated using probe radii of 1.4, 4, and 8 Å range from 6.17% to
42.06%, 0.01% to 20.23%, and 0.0% to 10.67% with the average values of 25.98%,
7.84%, and 3.06%, respectively. In general, the relative SASA values of the Nε atoms of
lysine residues on the enzyme surface decrease as the probe radius increases in both the
unglycosylated and glycosylated BChE models, demonstrating that a larger probe radius
or a larger PEGylation reagent has less chance to contact with the reaction sites (the Nε
atoms of lysine residues) and, thus, is expected to have a lower PEGylation reaction rate.
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Table 4.1 The relative SASA values of the Nε atoms of lysine residues on the surface of
human BChE calculated by using different probe radii.
SASA in unglyco-BChEa
SASA in glyco-BChEb
c
R = 1.4 Å
R=4Å
R=8Å
R = 1.4 Å
R= 4 Å
R= 8 Å
Lys9
43.70%d
21.05%
11.32%
42.06%
18.03%
8.03%
Lys12
45.99%
19.92%
10.51%
37.94%
16.95%
9.11%
Lys44
29.58%
7.93%
2.26%
20.64%
3.71%
0.40%
Lys45
27.86%
7.23%
1.75%
19.55%
2.57%
0.21%
Lys51
41.39%
16.52%
8.29%
41.73%
19.68%
10.00%
Lys60
35.19%
15.91%
8.18%
34.97%
14.13%
6.00%
Lys103
25.57%
4.40%
0.56%
29.25%
7.46%
1.52%
Lys105
42.93%
25.82%
16.97%
42.24%
20.23%
10.67%
Lys131
20.87%
2.53%
0.15%
17.85%
1.16%
0.01%
Lys180
25.71%
5.40%
1.67%
29.63%
7.11%
2.68%
Lys190
42.47%
22.43%
13.43%
33.37%
9.80%
2.30%
Lys248
39.73%
19.92%
10.40%
26.50%
5.93%
1.35%
Lys262
35.38%
16.16%
9.14%
33.63%
14.00%
6.52%
Lys267
29.02%
11.45%
5.25%
28.89%
11.24%
5.27%
Lys313
6.75%
0.64%
0.00%
9.72%
0.94%
0.07%
Lys314
35.78%
17.37%
10.50%
11.52%
1.96%
0.23%
Lys323
23.53%
6.55%
0.63%
31.00%
6.49%
0.36%
Lys339
32.99%
8.78%
2.02%
24.28%
5.19%
0.59%
Lys348
38.05%
19.40%
12.67%
33.84%
14.77%
6.88%
Lys355
31.37%
10.70%
4.46%
6.17%
0.14%
0.01%
Lys366
4.79%
0.31%
0.03%
7.72%
0.01%
0.00%
Lys407
20.69%
0.61%
0.00%
22.80%
0.57%
0.00%
Lys408
10.88%
0.60%
0.00%
12.22%
0.80%
0.01%
Lys427
10.35%
0.01%
0.00%
7.93%
0.00%
0.00%
Lys458
39.02%
18.53%
11.65%
26.86%
4.15%
0.22%
Lys469
14.93%
1.57%
0.09%
14.85%
0.19%
0.00%
Lys476
28.91%
2.46%
0.11%
17.11%
0.53%
0.00%
Lys494
41.90%
18.84%
11.47%
37.19%
14.29%
5.91%
Lys499
37.96%
17.04%
8.60%
37.31%
12.27%
1.23%
Lys513
31.80%
13.12%
6.45%
28.10%
11.37%
5.38%
Lys528
38.61%
18.47%
10.23%
38.37%
17.29%
9.83%
a
SASA of the Nε atom of lysine residues in the unglycosylated BChE.
Residue

b
c

SASA of the Nε atom of lysine residues in the glycosylated BChE.

R refers to the probe radius (1.4, 4, or 8 Å).

d

The relative SASA value refers to the calculated exposed percent of the surface area of

the Nε atom. The total surface area of the Nε atom (with a van der Waals radius of 1.55
Å)129 is 4π(R+1.55)2 in which R is the probe radius.
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To further analyze the steric hindrance of the glycosylation on the surface lysine
residues, those lysine residues that showed a significant decrease in SASA (when the
Percent of the Remain (POR) of SASA is less than 80%) are selected for further
discussion, and those residues are listed in Table 4.2. When the probe radius was 1.4 Å,
nine lysine residues were found to have a large decrease in SASA: Lys44, Lys45, Lys190,
Lys248, Lys314, Lys 339, Lys355, Lys458, and Lys476. This group of residues, denoted
as Group I for convenience, has the POR values ranging from 19.67% to 78.57%. When
the probe radius was increased to 4 Å, four more lysine residues (Lys105, Lys348,
Lys494, and Lys499) were added to the Group I, resulting in Group II (Lys44, Lys45,
Lys105, Lys190, Lys248, Lys314, Lys 339, Lys355, Lys348, Lys458, Lys476, Lys494,
and Lys499), with the POR values ranging from 1.31% to 76.13%. When the probe
radius was further increased to 8 Å, 15 lysine residues (i.e. the all the lysine residues
listed in Table 4.2, denoted as Group III for convenience) showed a large decrease in
SASA with the POR values ranging from 0.22% to 73.35%. Clearly, as the probe radius
increases, the number of lysine residues with larger POR values increases, suggesting that
the effects of the glycans on the PEGylation modification reactions are more significant
when a larger reagent is used.
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Table 4.2 The Percent of Remain (POR) of SASA of the Nε atoms of lysine residues on
BChE surface calculated using different probe radii
Residue R = 1.4 Åa
Lys44
69.78%b
Lys45
70.17%
Lys60
99.37%
Lys105
98.39%
Lys190
78.57%
Lys248
66.70%
Lys262
95.05%
Lys314
32.20%
Lys339
73.60%
Lys348
88.94%
Lys355
19.67%
Lys458
68.84%
Lys476
59.18%
Lys494
88.76%
Lys499
98.29%
a
R represents the probe radius (1.4, 4, or 8 Å).
b

R=4Å
46.78%
35.55%
88.81%
78.35%
43.69%
29.77%
86.63%
11.28%
59.11%
76.13%
1.31%
22.40%
21.54%
75.85%
72.01%

R=8Å
17.70%
12.00%
73.35%
62.88%
17.13%
12.98%
71.33%
2.19%
29.21%
54.30%
0.22%
1.89%
0.00%
51.53%
14.30%

The POR of SASA of the Nε atom of lysine residues in the glycosylated BChE

compared to SASA of the Nε atom of lysine residues in the unglycosylated BChE. POR =
SASA of the Nε in glycol-BChE / SASA of the Nε in (glycosylated) BChE.

To understand the relation between the lysine residues with the large decrease in
SASA and their locations on the enzyme surface, we searched for the lysine residues that
are located within a certain distance (4 or 8 Å) from each glycan. Specifically, the
distance between a lysine residue and a glycan is defined as the internuclear distance
between the Nε atom of the lysine and a glycan atom closest to the Nε atom. Based on the
collected snapshots of the MD-simulated structure, 12 lysine residues were found to
locate within 4 Å from a glycan: Lys44, Lys45, Lys60, Lys105, Lys190, Lys248, Lys313,
Lys314, Lys348, Lys355, Lys458, and Lys476 (denoted as Group IV). 17 lysine residues
were found to locate within 8 Å from a glycan: Lys44, Lys45, Lys60, Lys103, Lys105,
Lys190, Lys248, Lys261, Lys313, Lys314, Lys348, Lys355, Lys366, Lys427, Lys458,
Lys469, and Lys476 (denoted as Group V). Compared to Group IV, Group V, has five
more residues (Lys103, Lys261, Lys366, Lys427, and Lys469). However, according to
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the data in Table 4.1, Lys103, Lys366, Lys427, and Lys469 all have very small SASA
values calculated using all of the three probe radii in both the unglycosylated and
glycosylated BChE models. This means that, even without glycans on enzyme surface,
theses lysine residues are hardly available to contact with the PEGylation reagents. So,
ignoring these four lysine residues, Groups IV and V are almost the same, with Lys262
being the only additional lysine residue in Group V.
In comparison between Groups I and IV, it was noted that eight of the nine
residues in Group I were included in Group IV, suggesting that glycans on BChE surface
indeed mainly decrease the SASA of the Nε atoms of most lysine residues close to the
glycans. However, Lys339 in Group I was not included in Group IV. After inspecting the
location of Lys339, it was noted that Lys339 is located in an area surrounded by loop
residues (Gln71-Glu80, Tyr332-Asn341, and Glu421-Glu432). The glycan closest to
Lys339 is Glycan341, which is more than 10 Å away (see Figure 4.5 (A)). The large
decrease in SASA of the Nε atom of Lys339 may be due to the amino-acid residues
located in these highly flexible loops which may more significantly block the contact
between Lys339 and the probe in the glycosylated BChE. In fact, the RMSD values of
the backbone atoms of these loops (Gln71-Glu80, Tyr332-Asn341, and Glu421-Glu432)
in the MD-simulated glycosylated BChE were 0.84 Å, 1.27 Å, and 0.71 Å, respectively,
larger than the corresponding RMSD values of 0.77 Å, 1.19 Å, and 0.55 Å in the MDsimulated unglycosylated BChE. The glycans might not significantly change the overall
stability of the BChE protein as mentioned above, but they may increase the flexibility of
local protein structures. From this point of view, Lys399 is indirectly influenced by the
glycosylation. In Group I, Lys314 and Lys355 are affected most by the glycosylation
with the POR values being 32.20% and 19.67%, respectively. As seen in Figure 4.5 (B)
and (C), Lys314 is very close to some carbohydrate residues of Glycan106, and Lys355 is
almost fully blocked by several carbohydrate residues at the end of Glycan241.
Of the 13 lysine residues in Group II, 10 residues were included in Group IV.
Besides the aforementioned Lys339, residues Lys94 and Lys499 were also not included
in Group IV. These two residues were located in the same loop (Asn481-Lys499) and
they were very close to each other. Similar to Lys399, the large decrease in SASA of the
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Nε atom of Lys494 and Lys499 was likely due to the reason that the amino-acid residues
located in the highly flexible loop block the contact between Lys494/Lys499 and the
probe. The RMSD value of the backbone atoms of the loop where these two residues are
located in the MD-simulated glycosylated BChE was 1.22 Å, larger than that (0.90 Å) in
the MD-simulated unglycosylated BChE. The larger RMSD in the MD-simulated
glycosylated BChE was likely caused by Glycan481 and Glycan486 that are all
connected to the same loop as Lys494 and Lys499 (see Figure 4.5 (D) for the detail).
These computational data are consistent with previously reported experimental
observation that Asn481 and Asn486 must be mutated to glutamine residues to avoid the
glycosylation on these two sites and, thus, to obtain a single crystal for the X-ray
diffraction.92 The probe radius also plays an important role here. According to the data in
Table 4.2, a larger probe radius is associated with the smaller POR values, indicating that
larger reagents would amplify the influence of the glycosylation. The POR value of
Lys314 decreased from 32.20% associated with a probe radius of 1.4 Å to 11.28%
associated with a probe radius of 4 Å.
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Figure 4.5 Locations of representative lysine residues. The orange ribbons represent
BChE. The blue sticks represent the glycans. The cyan sticks refer to the linkage residue
asparagine. The green sticks represent the surrounding residues. The red ribbon refers to
the α helix where the Ser198 located. The pink sticks represent the lysine residues: (A)
Lys339; (B) Lys314; (C) Lys355; (D) Lys494 and Lys499.

Compared to the fact that Groups I and II only included some of the lysine
residues in Table 4.2, Group III included all of the 15 lysine residues in Table 4.2, which
further reflects the aforementioned observation that the steric hindrance of the
glycosylation on the lysine residues is more significant when a larger probe is used. In
comparison between Groups III and IV, 11 of the 14 lysine residues listed in Group III
are also listed in Group IV; the remaining four residues are Lys262, Lys339, Lys494, and
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Lys499. Of these four exceptions, three (i.e. Lys339, Lys494, and Lys499) have been
discussed above, and the only newly added one is Lys262. Notably, Lys262 is included in
Group V, suggesting this residue is still significantly affected by the glycosylation when a
larger PEGylation agent is used.

4.5 Conclusion
In the study described in this chapter, a 3D structural model of the glycosylated
human BChE has been developed to examine the effects of the glycosylation on the
possible PEGylation modification reactions. The calculated Solvent Accessible Surface
Area (SASA) values revealed that most surface lysine residues located within 8 Å, or
more precisely 4 Å, of glycans in the glycosylated BChE model have a significant
decrease in SASA compared to the corresponding SASA values in the unglycosylated
BChE, demonstrating the direct influence of the glycosylation. Three lysine residues
(Lys399, Lys494, and Lys499) that are not very close to the glycans still have a
significant decrease in SASA due to the indirect influence of the glycosylation.

Copyright @ Lei Fang 2013
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Chapter Five: Computational Design of Amino-Acid Mutations to Prolong the
Biological Half-life of a Highly Efficient Cocaine Hydrolase Engineered from
Human Butyrylcholinesterase

Our recently designed and discovered cocaine hydrolase, particularly E12-7
engineered from human butyrylcholinesterase (BChE), has the promise of becoming a
valuable cocaine abuse treatment. An ideal anti-cocaine therapeutic enzyme should have
not only a high catalytic efficiency against cocaine, but also a sufficiently long biological
half-life. However, recombinant human BChE and the known BChE mutants have a
much shorter biological half-life compared to the native human BChE. The present study
aimed to extend the biological half-life of the cocaine hydrolase without changing its high
catalytic activity against cocaine by using an integrated computational-experimental
approach. The strategy was to computationally design possible amino-acid mutations that
can introduce cross-subunit disulfide bond(s) and, thus, change the distribution of the
oligomeric forms and extend the biological half-life.

5.1 Overview of our strategy to prolong the biological half-life
In order to effectively suppress cocaine reward for a long period of time after
administration of an exogenous CocH, the therapeutic enzyme (CocH) should have not
only a high catalytic efficiency against cocaine, but also a sufficiently long circulation
time (biological half-life). Native human BChE has a biological half-life of ~24 hours in
mice and ~7 to 12 days in humans.130 However, recombinant forms of wild-type human
BChE and the known BChE mutants have a much shorter biological half-life compared to
the native human BChE.131 The difference between the native and recombinant human
BChE proteins in biological half-life is associated with the difference in the distribution
of the oligomeric forms and the post-translational modification. Native BChE consists of
more than 95% of tetramer, whereas predominant forms of recombinant BChE are
monomer and dimer.131,132 In addition, the native BChE is fully glycosylated with whole

61

nine N-linked oligosaccharides, whereas recombinant BChE is either not fully
glycosylated or close to native BChE.119,133-135
The present study aimed to extend the biological half-life of E12-7, i.e. the
A199S/F227A/S287G/A328W/Y332G mutant of human BChE, without changing its
catalytic activity against cocaine. It is very popular for extending the biological half-life
of a protein to chemically modify the protein surface with polyethylene glycol (PEG).
However, it is well-known that PEG can elicit an immune response in humans.136-138 For
this reason, we are reluctant to PEGylate the human protein which is accommodated
perfectly in humans. We prefer to extend the biological half-life of E12-7 through
rationally designed further mutations on its amino-acid residues that are not available for
intermolecular interactions with any other proteins in the body; such type of amino-acid
mutations is not expected to produce immune response.
On the other hand, it is a grand challenge to design amino-acid mutations that can
extend the biological half-life of a protein, although computational design has been used
successfully to identify thermostable mutants of proteins. This is because the biological
half-life of a protein is determined by many factors, in addition to the thermostability. For
a protein to have a desirably long biological half-life, the protein must be thermostable
enough at the body temperature (37oC) to have an in vitro half-life at 37oC which is at
least not shorter than the desirable biological half-life. So, when a protein has a short
biological half-life because the protein is thermally unstable, one may computationally
design a thermostable mutant of the protein to extend the biological half-life.62 However,
for most proteins, their short biological half-lives are due to factors other than the
thermostability. Specifically for the therapeutically interesting protein concerned in the
study described in this chapter, BChE (wild-type or the mutant) is very thermostable at
37oC. But the recombinant form of the thermostable protein is quickly eliminated from
the body. So, further improving the protein thermostability is not expected to extend its
biological half-life. One must account for other factors affecting the biological half-life.
In the study described in this chapter, computational modeling of E12-7 was
performed to design further amino-acid mutations that can favorably change the
distribution of the oligomeric forms and, thus, extend the biological half-life. In particular,
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the computational design was focused on possible mutations that may introduce disulfide
bond(s) between different subunits in the multimeric forms (dimer and tetramer) and,
thus, stabilize the multimeric forms and decrease the concentration of the monomer. This
computational design strategy was based on the observation that the multimeric forms of
BChE have a longer biological half-life compared to the monomer. The computational
design was followed by experimental studies in vitro and in vivo, leading to discovery of
novel BChE mutants that not only retain the high catalytic activity of E12-7 against
cocaine, but also have a significantly prolonged biological half-life, demonstrating that it
is possible to computationally design amino-acid mutations on therapeutic proteins with a
prolonged biological half-life without changing the biological functions.

5.2 Computational methods used to performed for the mutant design
The initial BChE structure modeled in the study described in this chapter came
from our previously reported computational study on the BChE tetramer.139 Based on the
tetramer structure, the tetramer consists of two equivalent dimers, and the computational
design was focused on the amino acid residues on the inter-subunit interface within a
dimer. The procedure for carrying out the molecular dynamics (MD) simulation on the
dimer in this study was similar as that used in section 2.2 of chapter 2. All molecular
mechanics optimization and MD simulation were carried out by using the AMBER 9
program package.122,140 The MD simulation was performed under normal temperature
(300 K) for 50 ns.

5.3 Methods for in vitro studies
5.3.1 Materials used for in vitro studies
Cloned Pfu DNA polymerase and DpnI endonuclease were obtained from
Stratagene (La Jolla, CA). All oligonucleotides were synthesized by the Eurofins
(Huntsville,AL). The QIAprep Spin Plasmid Miniprep Kit was obtained from QIAGEN
(Valencia, CA). Chinese hamster ovary (CHO) cells and culture medium were from life
technologies (Grand Island, NY). The transfection kit was from Mirus Bio LLC (Madison,
WI). Anti-BChE (mouse monoclonal antibody) was purchased from AntibodyShop
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(Gentofte, Denmark), and goat anti-mouse IgG HRP conjugate was from Zymed
Laboratories (South San Francisco, CA). [3H](−)-Cocaine (50 Ci/mmol) was purchased
from PerkinElmer Life and Analytical Sciences (Waltham, MA). QFF ion exchanger was
from GE Healthcare.

5.3.2 Site-directed mutagenesis
Site-directed mutagenesis of human BChE cDNA was performed by using the
QuikChange method.141 Further mutations required to produce a new BChE mutant
cDNA

were

generated

from

the

cDNA

corresponding

to

the

A199S/F227A/S287G/A328W/Y332G mutant of human BChE in a pRc/CMV expression
plasmid.142 Using plasmid DNA as template and primers with specific base-pair
alterations, mutations were made by polymerase chain reaction with Pfu DNA
polymerase for replication fidelity. The PCR product was treated with DpnI endonuclease
to digest the parental DNA template. The digested product was transformed into
Escherichia coli, amplified, and purified. The DNA sequences of the mutants were
confirmed by DNA sequencing.

5.3.3 Protein expression
The A199S/F227A/S287G/A328W/Y332G BChE and newly designed BChE
mutants were expressed in CHO-S cells in free-style CHO expression medium. Cells
were first grown to a density of ~1.0 × 106 in 1L shake flask and transfected using
TransIT-PRO Transfectio Kit. Cells were incubated at 37°C in a CO2 incubator for 6 days.
The culture medium was then harvested for the BChE activity assays.

5.3.4 Protein purification
Purification of each enzyme mutant in medium was achieved by using an ion
exchange chromatography. In brief, 1L of medium with a BChE mutant was diluted with
the same volume of 20 mM Tris-HCl, pH 7.4. Pre-Equilibrated QFF anion exchanger was
added to the diluted medium in 1% of its volume and incubated at 4°C with shaking (100
rpm) overnight. More than 95% enzyme activity was found to bind to the resin after the
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incubation. The suspension was then packed in a column (5 × 50 cm), and the medium
was allowed to flow through rapidly with the aid of suction (50–100 ml/min). The QFF
resin was repacked again in a washing buffer after all of the medium was excluded. After
washing the column with 20 mM Tris-HCl, pH 7, the enzyme was eluted by 20 mM TrisHCL, pH 7.0, plus 0.3 M NaCl. The eluate was concentrated and changed to phosphatebuffered saline by Millipore centrifugal filter device. Finally, the purified enzyme was
stored at 4°C or −80°C. The entire purification process was carried out in cold room at
4°C.

5.3.5 Gels stained for enzyme activity
8% non-denaturing polyacrylamide gels were run at constant current of 8 mA at
4 °C, overnight. The gels were stained for BChE activity with 1 mM butyrylthiocholine
iodide as substrate in the Karnovsky and Roots staining procedure.143

5.3.6 Enzyme activity assays
To measure (−)-cocaine and benzoic acid, the product of (−)-cocaine hydrolysis
catalyzed by BChE, sensitive radiometric assays were used based on toluene extraction of
[3H](−)-cocaine labeled on its benzene ring.130 In brief, to initiate the enzymatic reaction,
100 nCi of [3H](−)-cocaine was mixed with culture medium. The enzymatic reactions
proceeded at room temperature (25°C) with varying concentrations of (−)-cocaine. The
reactions were stopped by adding 200 μl of 0.1 M HCl, which neutralized the liberated
benzoic acid whereas ensuring a positive charge on the residual (−)-cocaine. [3H]Benzoic
acid was extracted by 1 ml of toluene and measured by scintillation counting. Finally, the
measured (−)-cocaine concentration-dependent radiometric data were analyzed by using
the standard Michaelis-Menten kinetics so that the catalytic parameters were determined
along with the use of a well-established standard enzyme-linked immunosorbent assay
protocol.104
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5.4 Methods for in vivo studies
Sprague-Dawley (Male or female) rats (200-250 g) were obtained from Harlan
(Indianapolis, IN) and were housed in groups of 2 to 4 per cage. All rats were allowed ad
libitum access to food and water, and were maintained on a 12-h light-dark cycle with
lights on at 8 AM in a room kept at a temperature of 21-22°C. Each rat was used only
once. Experiments were performed in the same colony room in accordance with the
Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the
National Institutes of Health. The experimental protocols were approved by the
Institutional Animal Care and Use Committee (IACUC) at the University of Kentucky.
Purified BChE mutants (0.15 mg/kg) were injected intravenously (i.v., via tail
vein) into rats. After the enzyme injection, around 50-75 μl blood was collected into a
capillary tube from the saphenous veins at different time points (2 min, 15 min, 30 min, 1
hr, 2 hr, 3 hr, 5 hr, 8 hr, 12 hr, 24 hr, 48 hr, and 72 hr). Serum isolated by centrifugation
(5000 g, 15 min) from the blood sample will be used for analysis using the in vitro
enzyme activity assays mentioned above. The time-dependent concentrations of the
enzyme in plasma were fitted to a double-exponential equation described by Kronman.144

5.5 BChE mutant design: Insights from molecular modeling
The goal of the study described in this chapter was to design new BChE mutants
that had a prolonged biological half-life without a significant change in the high catalytic
activity of E12-7 against (-)-cocaine. The new computational design strategy relies on the
MD-simulated dynamic structure of the BChE dimer and the idea that the BChE
monomers can be covalently bonded to form covalent dimers by introducing
intermolecular disulfide bond(s). So, we have carried out a long MD simulation (50 ns)
on the BChE dimer structure in order to obtain a dynamically stable BChE dimer
structure. To search for appropriate mutational sites to introduce the cross-subunit
disulfide bond(s), a self-developed script was used to scan the key internulcear distances
between the Cα atoms of the residues on the dimer interface from the snapshots extracted
from MD trajectory. Essentially, each pair of residues from different subunits was
evaluated computationally for the simulated Cα–Cα distance. If the simulated Cα–Cα
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distance was within 7 Å, the pair of the residues would be checked manually for further
evaluation of the detailed interactions. The most hopeful pairs of residues may be
mutated to cystines for introducing possible cross-subunit disulfide bond(s).
Table 5.1 The Cα-Cα distances between key residues in various dimer/tetramer BChE
structures obtained from computational modeling/simulation.
Cα-Cα distance (Å)

F364a

F364b

V377a

V377b

N535a

-

-

-

-

-

M532b

M532a

A516b

A516a

N535b

BChE model Aa

9.02

9.31

5.83

6.20

N/A

BChE model Bb

9.98

10.29

8.15

8.82

9.07

Maximum

10.71

8.08

15.70

10.47

10.84

Minimum

5.33

4.42

4.71

5.56

4.53

Average

7.93

5.61

7.73

6.89

6.83

BChE structure

MD-simulated BChE
structure (50 ns MD)c
a

A simple homology model of BChE tetramer obtained from the homology modeling

using the X-ray crystal structure of Electrophorus electricus AChE (EeAChE) tetramer
(PDB ID: 1C2O)94 as a template. Because the simple homology modeling was based on
the sequence alignment only (without any energy minimization or MD simulation on the
backbone), the Cα-Cα distances between F364 and M532 in the BChE tetramer are
simply the corresponding Cα-Cα distances between L373 and A542 in the EeAChE
tetramer, and the Cα-Cα distances between V377 and A516 in the BChE tetramer are
simply the corresponding Cα-Cα distances between L386 and A526 in the EeAChE
tetramer. The sequence alignment indicates that N535 in BChE corresponds to T545 in
EeAChE which is not available missing in the X-ray crystal structure.
b

BChE tetramer model obtained from the combined use of the X-ray crystal structures of

the EeAChE tetramer (PDB ID: 1C2O) and the BChE monomer (PDB ID: 1P0M)92; each
subunit of the EeAChE tetramer was superimposed with the BChE monomer139 in order
to obtain the BChE tetramer (with the backbone frozen during the energy minimization
and MD simulation).
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c

Fully relaxed MD simulation of the BChE dimer structure starting from the BChE model

B. The maximum, minimum, and average values of the Cα-Cα distances refer to the
stable MD trajectory (10 to 50 ns).

Figure 5.1 The time-dependent Cα–Cα distances between key residues from different
subunits (a and b) in the MD-simulated BChE dimer structure: (A) F364 and M532; (B)
V377 and A516; and (C) N535.

As seen in Table 5.1, the detailed analysis of the MD trajectory predicted that
mutations F364C/M532C, V377C/A516C, and N535C may introduce the desirable crosssubunit disulfide bond(s). Depicted in Figure 5.1 are the simulated time-dependent Cα–
Cα distances for these pairs of the residues. Depicted in Figure 5.2 (A) is the MDsimulated BChE dimer structure consisting of subunits a and b. Figure 5.2 (B)–(G) shows
the details of the MD-simulated BChE dimer structure concerning these important pairs
of residues. The interface is mainly composed of 4 α helices (A516a – M532a, E363a –
Y373a, A516b – M532b, and E363a – Y373b) and several loop parts. F364 is located on
one α helix (E363a – Y373a), M532 is located on the end of one α helix (A516b – M532b)
as shown in Figure 5.2 (B) and (C). V377 is located on the loop part of the interface. The
location of A516 is similar to that of M532. Both A516 and M532 are located on the
same α-helix (A516 – M532), with A516 being on the head and M532 being on the end
of the α-helix.
According to the locations of these residues, it is possible to introduce a pair of
cross-subunit

disulfide

bonds

(C364a-C532b

and

C532a-C364b)

through

the

F364C/M532C mutations on E12-7. The computationally designed new mutant, i.e. the
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A199S/F227A/S287G/A328W/Y332G/F364C/M532C mutant (denoted as E364-532 for
convenience), may have a pair of cross-subunit disulfide bonds: one between C364 of
subunit a (C364a) and C532 of subunit b (C532b), and the other between C532 of subunit
a (C532a) and C364 of subunit b (C364b). Similarly, the V377C/A516C mutations may
also introduce a pair of cross-subunit disulfide bonds (C377a-C516b and C516a-C377b),
and

the

designed

new

mutant,

i.e.

the

A199S/F227A/S287G/A328W/Y332G/V377C/A516C mutant, is denoted as E377-516
for convenience. In addition, we noted in the simulated E12-7 structure that N535 was
right in the middle of the interface, so that N535a and N535b from the two subunits are
close to each other. For this reason, a single mutation on N535 (i.e. the N535C mutation)
may introduce a single cross-subunit disulfide bond (C535a-C535b). The designed new
mutant, i.e. the A199S/F227A/S287G/A328W/Y332G/N535C mutant, is denoted as E535
for convenience. It is also interesting to note that residues V377, M532, and N535 are
either on the loop or next to the loop, implying that the positions of these residues have
some flexibility which may help to form the desirable cross-subunit disulfide bonds.
As noted above, the computational prediction was based on the MD-simulated
dynamically stable BChE dimer structure. For comparison, we also examined two static
models of the BChE tetramer structures. One was a simple model of BChE tetramer
(BChE model A in Table 5.1) obtained from the homology modeling using the X-ray
crystal structure of Electrophorus electricus AChE (EeAChE) tetramer (PDB ID: 1C2O)94
as a template. The other one was a BChE tetramer model (BChE model B in Table 5.1)139
obtained from the combined use of the X-ray crystal structures of the EeAChE tetramer
(PDB ID: 1C2O) and the BChE monomer (PDB ID: 1P0M).92 As seen in Table 5.1,
based on BChE model A, we could only predict the possible cross-subunit disulfide
bonds that can be introduced by the V377C/A516C mutations. As seen in Table 5.1,
based on BChE model B, we could not predict any of the aforementioned cross-subunit
disulfide bonds.
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Figure 5. 2 (A) The modeled BChE dimer structure (subunits a and b). (B) Key residues
F364 (a/b) and M532 (a/b) on the dimer interface. (C) Cross-subunit disulfide bonds
formed on the interface of E364-532 by C364a-C532b and C532a-C364b. (D) Key
residues V377 (a/b) and A516 (a/b) in the dimer interface. (E) Cross-subunit disulfide
bonds formed on the interface of E377-516 by C377a-C516b and C516a-C377b. (F) Key
residues N535 (a/b) on the dimer interface. (G) Cross-subunit disulfide bond formed on
the interface of E535 by C535a-C535b. Different subunits are shown in different colors:
subunit a in green and subunit b in orange. The active-site residues are shown in pink.
Key residues are colored in blue and red using the ball-and-stick model. E364-532 refers
to A199S/F227A/S287G/A328W/Y332G/F364C/M532C BChE.

5.6 Oligomeric forms of the proteins
Based on the computational insights, we carried out in vitro experimental tests,
including site-directed mutagenesis, protein expression and purification, on the E12-7,
E364-532, E377-516, and E535 under the same experimental conditions. Depicted in
Figure 5.3 are nondenaturing gels (8%) stained for the BChE activity. As shown in Figure
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5.3, E12-7 exists in a mixture of the monomer (~70%), dimer (~10%), and tetramer
(~20%), whereas E364-532, E377-516, and E535 only exist in the dimer (~80%) and
tetramer (~20%) without the monomer at all. The data shown in Figure 5.3 indicate that
the desirable cross-subunit disulfide bonds were likely formed in the designed enzymes
E364-532, E377-516, and E535, and that formation of the cross-subunit disulfide bond(s)
can help to completely eliminate the monomer and increase the dimer concentration.

Figure 5.3 Nondenaturing gels (8%) stained for the BChE activity of (A) E12-7, (B)
E364-532, (C) E377-516, and (D) E535. The gels were run with the constant current of 8
mA at 4°C overnight. The gels were stained for the BChE activity with
butyrylthiocholine iodide as substrate at room temperature until the protein bands with
the

enzymatic

activity

were

clearly

identified.

A199S/F227A/S287G/A328W/Y332G/F364C/M532C

BChE,

E364-532
E377-516

refers
refers

to
to

A199S/F227A/S287G/A328W/Y332G/V377C/A516C BChE, and E535 refers to
A199S/F227A/S287G/A328W/Y332G/N535C BChE.
5.7 Catalytic activity against (−)-cocaine
Knowing the effects of the computationally designed mutations on the distribution
of the oligomeric forms of the enzyme, we further carried out the in vitro enzyme activity
assays to determine the effects of the same mutations on the catalytic activity of the
enzyme against (−)-cocaine. To minimize the possible systematic experimental errors of
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in vitro kinetic analysis, we expressed the enzymes and performed kinetic studies on E127 and the new mutants (E364-532, E377-516 and E535) at the same time under the same
experimental conditions, and compared the catalytic activity of the new mutants to that of
E12-7 against (-)-cocaine. Depicted in Figure 5.4 are the kinetic data, and summarized in
Table 5.2 are the determined kinetic parameters. As summarized in Table 5.2, the
catalytic parameters of the computationally designed new BChE mutants are very close to
or essentially the same as corresponding catalytic parameters of E12-7 against (-)-cocaine.
In terms of the KM values, only E377-516 has a slightly larger KM value (3.8 µM)
compared to that (3.1 µM) of E12-7. Concerning the kcat values, E535 and E12-7 have a
very similar kcat value (5700 min-1 for E12-7 and 5770 min-1 for E535) with a negligible
difference (70 min-1 which might be within the possible experimental errors). The kcat
values of E364-532 and E377-516 are slightly lower than that of E12-7. So, we may say
that the computationally designed mutations have remarkably changed the distribution of
the oligomeric forms of the enzyme without significantly affecting the high catalytic
activity of E12-7 against (-)-cocaine.
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Figure 5.4 Kinetic data for the hydrolysis of (-)-cocaine catalyzed by BChE mutants: (A)
E12-7; (B) E364-532; (C) E377-516; and (D) E535. The reaction rates were determined
by using a sensitive radiometric assays based on toluene extraction of [3H](-)-cocaine
labeled

on

its

benzene

ring.

A199S/F227A/S287G/A328W/Y332G/F364C/M532C

E364-532
BChE,

refers

E377-516

refers

to
to

A199S/F227A/S287G/A328W/Y332G/V377C/A516C BChE, and E535 refers to
A199S/F227A/S287G/A328W/Y332G/N535C BChE.
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Table 5.2 Kinetic parameters determined for (-)-cocaine hydrolysis catalyzed by the
BChE mutants.

a

Enzyme

KM (µM)

kcat (min-1)

kcat/KM (M-1 min-1)

E12-7a

3.1

5700

1.8×109

E364-532

3.1

4650

1.5×109

E377-516

3.8

4980

1.3×109

E535

3.1

5770

1.9×109

E12-7 refers to A199S/F227A/S287G/A328W/Y332G BChE, E364-532 refers to

A199S/F227A/S287G/A328W/Y332G/F364C/M532C

BChE,

E377-516

refers

to

A199S/F227A/S287G/A328W/Y332G/V377C/A516C BChE, and E535 refers to
A199S/F227A/S287G/A328W/Y332G/N535C BChE.

5.8 Biological half-life
Based on the encouraging in vitro data discussed above, we further tested E12-7,
E364-532, E377-516, and E535 in vivo for their pharmacokinetic in rats. First of all, five
rats (n=5) were tested for E12-7 to determine its biological half-life as the standard
reference. For comparison, the other three enzymes (E364-532, E377-516, and E535)
were also tested for their biological half-lives in rats. Depicted in Figure 5.5 were the
time-dependent average concentrations of the enzymes in plasma after the i.v. injection of
the enzymes. It had been well-known that measured time-dependent concentrations of the
active enzyme [E] in plasma follows a double exponential equation, i.e.
[ E ]  A exp( 1t )  B exp(  2 t ) , which accounts for both the enzyme distribution process

(the fast phase, associated with α1) and elimination process (the slow phase, associated
with α2). The elimination half-life was also known as the biological half-life. Analysis of
the time courses depicted in Figure 5.5 revealed the biological half-lives of the enzymes.
The determined biological half-life of E12-7 was 7.3 hr in rats. With the cross-subunit
disulfide bond(s), the computationally designed new mutants all had a significantly
prolonged biological half-life which was 13.2, 13.1, and 13.3 hr for E364-532, E377-516,
and E535, respectively. So, the computationally designed new enzymes (E364-532,
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E377-516, and E535) indeed had a significantly prolonged biological half-life in rats
without significantly changing the high catalytic activity of E12-7 against (-)-cocaine.

Figure 5.4 Time-dependent concentrations of the active enzyme in rat plasma after the i.v.
injection of the enzyme at a dose of 0.15 mg/kg: (A) E12-7, (B) E364-532, (C) E377-516,
and (D) E535. E12-7 refers to A199S/F227A/S287G/A328W/Y332G BChE, E364-532
refers to A199S/F227A/S287G/A328W/Y332G/F364C/M532C BChE, E377-516 refers
to A199S/F227A/S287G/A328W/Y332G/V377C/A516C BChE, and E535 refers to
A199S/F227A/S287G/A328W/Y332G/N535C BChE.

The in vivo data suggest that the new mutants, particularly E535, could be more
valuable than E12-7 in the future further development of a cocaine abuse treatment. It has
been known that, for a given therapeutically useful enzyme, the biological half-life in
humans is usually much longer than that in rats. As noted above, the biological half-life
of the native human BChE is ~24 hr in mice and ~7 to 12 days in humans. Assuming that
the biological half-life of a BChE mutant in humans is at least 7-fold longer than that in
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mice and rats, then we may theoretically predict the biological half-lives of the BChE
mutants in humans from their biological half-lives in rats. Thus, E12-7 (with a biological
half-life of ~7 hr in rats) is expected to have a biological half-life of at least two days in
humans, and the newly designed enzymes (E364-532, E377-516, and E535, all with a
biological half-life of ~13 hr in rats) are expected to have a biological half-life of about
four days or longer in humans.

5.9 Conclusion
The MD simulation on the dimer structure of a promising cocaine hydrolase, i.e.
E12-7 engineered from human BChE, led us to predict that the F364C/M532C,
V377C/A516C, and N535C mutations can produce cross-subunit disulfide bond(s) in the
enzyme and, thus, stabilize the dimer structure. Based on the MD simulation, three new
mutants of human BChE (E364-532, E377-516, and E535) were predicted to have a more
stable dimer structure with the desirable cross-subunit disulfide bond(s) and, therefore, a
different distribution of the oligomeric forms and a prolonged biological half-life.
Following the computational prediction, in vitro and in vivo experimental studies have
demonstrated that the computationally designed new BChE mutants, i.e. E364-532,
E377-516, and E535, indeed have a remarkably different distribution of the oligomeric
forms (dimer and tetramer) without monomer at all and a significantly prolonged
biological half-life in rats. The computationally designed new mutations (F364C/M532C,
V377C/A516C, and N535C) have successfully extended the biological half-life of E12-7
in rats from ~7 hrs. to ~13 hrs., without significantly changing the high catalytic activity
of E12-7 against (-)-cocaine. The newly designed and discovered BChE mutants,
particularly E535, could be more valuable than E12-7 in the future development of a
novel enzyme therapy for cocaine abuse. The encouraging outcomes of the present study
suggest that the structure-and-mechanism-based computational design and integrated
computational-experimental approach are promising for rational protein design,
discovery, and development. The general computational protein design strategy and
approach may also be valuable for engineering other proteins.
Copyright @ Lei Fang 2013
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Chapter Six: Design, Preparation, and Characterization of Cocaine Esterase against
Cocaine Toxicity with Improved Activity and Thermostability

Bacterial cocaine esterase (CocE) was known as the most efficient natural enzyme
for metabolizing the naturally occurring (-)-cocaine, suggesting that it might be a
promising candidate in treating cocaine overdose and addiction. However, a major
obstacle of wild-type CocE is the thermoinstability and short biological half-life. The
present study aimed to extend the thermostability and biological half-life of CocE by
introducing cross-subunit disulfide bonds and PEGylaion modification.

6.1 Overview of the CocE engineering
Bacterial cocaine esterase (CocE) was recognized as the most efficient natural
enzyme for metabolizing the naturally occurring (-)-cocaine.51 Studies have shown that
CocE can help prevent extreme cocaine toxicity and even from the lethal effects of
cocaine52. However, a major obstacle to the clinical application of CocE is the
thermoinstability of wild-type CocE with a half-life of only a few minutes at
physiological temperature (37°C).62 It is highly desirable to develop thermostable
mutants of CocE for therapeutic treatment of cocaine toxicity.
To improve enzyme thermostability, two strategies are normally used with the
purpose of improving the weak interactions inside the enzymes by either through noncovalent forces, such as hydrogen bond,145 or through covalent linkage, such as disulfide
bond.146 Besides improving the stability of the enzyme, it is also important to maintain
the activity of the enzyme. Based on a commonly accepted “stability-function theory”,147
there is a balance between protein stability and protein function, especially for enzyme.
Enzymes fold from amino acid sequences to their tertiary structures to form the
hydrophobic interiors and hydrophilic exteriors, in other words, from unstable amino acid
sequences to stable structures. Structure flexibility of enzyme is important for facilitating
its binding and reaction with a substrate. Thus, improving enzyme stability may possibly
lead to decrease/loss of the enzyme activity. So, it is challenging to improve the
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thermostability of an enzyme without decreasing its catalytic activity,147,148 and it is
extremely rare to simultaneously improve both the thermostability and catalytic
activity.149 However, one of the CocE mutants, i.e. the T172R/G173Q CocE, designed in
our lab has a ~30-fold improved thermostability (in terms of the in vitro half-life at 37oC)
compared to the wild-type CocE and maintains its catalytic activity against cocaine,62
giving us the hope to design new CocE mutants with improved thermostability without
interfering with its activity against cocaine.
T172R/G173Q CocE (denoted as E172-173 for convenience) was designed
through introducing favorable non-covalent force including a hydrogen bond between
domains I and II.62 In this study, we aimed to further extend the thermostability of E172173 through covalent bonding, i.e. by introducing disulfide bonds. Our design strategy
relies on the MD-simulated structure of the CocE dimer and the idea that the dimer
structure can be stabilized by introducing disulfide bonds between the two subunits of the
dimer.54 The computational design was followed by in vitro experimental studies, leading
to the discovery of a new CocE mutant that has a significantly improved thermostability
and an improved catalytic efficiency against cocaine as well. The new mutant was
modified further via PEGylation. The PEGylated CocE mutant was used to fully protect
mice from a lethal dose of cocaine (180 mg/kg, LD100) for at least three days, indicating
that it might be a more promising candidate for development of novel anti-cocaine
therapeutics. In addition, the integrated computational-experimental studies may also be
valuable for other protein drug design, discovery, and development efforts that aim to
treat other drugs of abuse or metabolic diseases.

6.2 Computational methods used for the mutant design
The starting CocE dimer (E172-173) structure was taken from the X-ray crystal
structure (deposited at Protein Data Bank) at 2.0 Å resolution (PDB ID: 3I2F54). The
general procedure for carrying out the molecular dynamic (MD) simulations was similar
to that used in section 2.2 of chapter 2. Briefly, all molecular mechanics optimization and
MD simulations were carried out by using the AMBER 9 program package. A 50-ns MD
simulation was performed under the normally adopted temperature (300 K).
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6.3 Methods for in vitro studies
6.3.1 Site-directed mutagenesis
Similar to the procedure described in Chapter 5, for the study described in this
chapter, point mutations were also generated using QuikChange method.141 Further
mutations required to produce a new CocE mutant cDNA were generated from the cDNA
corresponding to the E172-173 in the pET-22b (+) bacterial expression vector. All
mutants were sequenced in both directions over the entire coding region. Using plasmid
DNA as template and primers with specific base-pair alterations, mutations were made by
polymerase chain reaction with Pfu DNA polymerase for replication fidelity. The PCR
product was treated with DpnI endonuclease to digest the parental DNA template. The
digested product was transformed into Escherichia coli, amplified, and purified. The
DNA sequences of the mutants were confirmed by DNA sequencing.

6.3.2 Protein expression and purification
The CocE mutants were expressed in Escherichia coli BL-21 (DE3) cells grown
at 37 °C. Protein expression was induced with 1 mM isopropyl-β-thiogalactopyranoside
(Sigma Aldrich) for ~15 h at 18°C. Cells were pelleted, resuspended in 50 mM Tris-HCl,
pH 8.0, 150 mM NaCl buffer with protease inhibitor cocktail (Sigma) and lysed using a
French press (Thermo Fisher Scientific). The 6His-tagged enzymes were then enriched
using HisPur cobalt resin (Thermo Fisher Scientific). The eluted fractions were
concentrated by using an Amicon Ultra-50K centrifuge (Millipore, Billerica, MA). The
enzyme concentrations were determined using a CB-Protein Assay kit (from
CALBIOCHEM) with bovine serum albumin as a standard.

6.3.3 Enzyme activity assays
The procedure of enzyme activity assays is the same as that described in Chapter
5. To test the thermostability of the mutants, enzymes were diluted to 200 μg/ml, stored
in sealed glass tubes and incubated at 37°C. One tube will be taken out of the incubation
cabinet at various time points (0, 2, 9, 12, 31, and 100 days ) and assayed for activity
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against (-)-cocaine as mentioned above. The percentage of remaining activity was plotted
against time to assess the half-life of each enzyme.

6.3.4 Melting temperature measurements
Circular Dichroism (CD) data were collected on a J-810 spectropolarimeter
(JASCO, Easton, MD). UV wavelength of 280 nm was used to run with temperature
increasing from 10°C to 60°C in 1°C increments, and a 1-cm pathlength water-jacketed
cylindrical quartz cell.

6.3.5 PEGylation
Purified enzyme was conjugated with maleimide-linked branched PEG with
molecular weight of 40 KDa (JenKem Technology) overnight in PBS buffer, pH 7.4 at
the PEG to enzyme ratio of 20.

6.4 Methods for in vivo studies
Similar to the description of rats in Chapter 5, for the study described in this
chapter, male CD-1 mice (25−30 g) were purchased from Harlan (Indianapolis, IN) and
were housed in groups of four mice per cage. All mice were allowed ad libitum access to
food and water and were maintained on a 12 h light−dark cycle with lights on at 6:30 a.m.
in a room kept at a temperature of 21−22°C. Experiments were performed in accordance
with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated
by the National Institutes of Health. The experimental protocols were approved by the
Institutional Animal Care and Use Committee (IACUC) at the University of Kentucky.
The purified enzyme was administrated intravenously (i.v., via tail vein) and (-)Cocaine HCl (obtained from National Institute on Drug Abuse, Bethesda, MD) was
administered intraperitoneally, at a volume of ~0.2 mL/mouse. Cocaine-induced toxicity
was characterized by the occurrence of lethality. Lethality was defined as cessation of
observed movement and respiration. A single dose (30 mg/kg) of E196-301 or PEGylated
E196-301 was administered intravenously 1 min before the first intraperitoneal
administration of 180 mg/kg cocaine (n=5). The mice were challenged daily with 180
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mg/kg cocaine until no mouse survived. Following cocaine administration, mice were
immediately placed individually for observation. The presence or absence of lethality was
recorded for 60 min following cocaine administration.

6.5 CocE mutant design: Insights from molecular modeling
The goal of the study described in this chapter was to design CocE mutants that
have an improved thermostability. Our new computational design strategy relied on the
MD-simulated structure of the CocE dimer and the idea that the dimer structure can be
stabilized by introducing disulfide bonds between the two subunits of the dimer. So, we
carried out a long MD simulation (50 ns) on the CocE dimer structure in order to obtain a
dynamically stable dimer structure. To search for appropriate mutational sites to
introduce the cross-subunit disulfide bonds, a self-developed script was used to scan the
key internulcear distances between the Cα atoms of the residues on the dimer interface
from the snapshots extracted from MD trajectory as described in chapter 5.

Figure 6.1 The time-dependent Cα–Cα distances between L196 and I301 during the
whole MD simulation in CocE dimer. Here a and b indicated after the residue numbers
refer to subunits a and b, respectively.
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Table 6.1 The Cα-Cα distances between key residues in CocE dimer obtained from
computational simulation.
Cα–Cα distances (Å)

L196a – I301b

I301a – L196b

7.29

7.20

Maximum

10.85

7.19

Minimum

5.16

4.51

Average

7.15

5.44

CocE structure
CocE crystal structurea
MD-simulated CoCE
structure (50 ns MD)b
a
b

T172R/G173Q CocE crystal structure, PDB ID: 3I2F.
Fully relaxed MD simulation of the CocE dimer structure starting from the

T172R/G173Q CocE crystal structure. The maximum, minimum, and average values of
the Cα-Cα distances refer to the stable MD trajectory (10 to 50 ns).

As seen in Table 6.1, the detailed analysis of the MD trajectory predicted that
extra mutations L196C/I301C may introduce the desirable cross-subunit disulfide bonds
between the subunits of E172-173. Depicted in Figure 6.1 are the simulated timedependent Cα–Cα distances for the pair of the residue. Depicted in Figure 6.2(A) is the
MD-simulated CocE dimer structure consisting of subunits a and b. Figure 6.2(B) is the
detail of the MD-simulated CocE dimer structure concerning this important pair of
residues. The interface between the two subunits is mainly composed of some residues
from all the domains (I, II, and III) in the form of α-helixs, β-sheets, and loops. L196 is
located on one α-helix (E184-N197) in domain II, I301 is located on one loop in domain I.
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Figure 6.2 (A) The modeled CocE dimer shown in ribbons (with a and b referring to
subunits a and b, respectively), domain I is shown in red, domain II is shown in green,
and domain III is shown in yellow. (B) Key residues L196 (a/b) and I301 (a/b) shown in
ball and sticks on the dimer interface.

According to the locations of these residues, it is highly possible to introduce two
pairs of cross-subunit disulfide bonds (C196a-C301b and C301a-C196b) through the
L196C/I301C/ mutations on E172-173. The computationally designed new mutant, i.e.
the T172R/G173Q/L196C/I301C mutant (denoted as E196-301 for convenience), may
have a pair of cross-subunit disulfide bonds: one between C196 of subunit a (C196a) and
C301 of subunit b (C301b), and the other between C301 of subunit a (C301a) and C196
of subunit b (C196b). It is also interesting to note that residue I301 is on the loop,
implying that the loop flexibility may help to form the desirable cross-subunit disulfide
bonds.
Also as noted above, our computational prediction was based on the MDsimulated dynamically stable CocE dimer structure. For comparison, we also examined
the static crystal structure of the CocE dimer. As seen in Table 6.1, based on the crystal
structure, we could not predict any of the aforementioned cross-subunit disulfide bonds.

6.6 Thermostability assessment
Based on the computational insights, we carried out wet experimental tests,
including site-directed mutagenesis, protein expression, purification, and enzyme activity
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assays on the E172-173 and E196-301. To minimize the possible systematic experimental
errors of the kinetic data, we expressed the enzymes and performed the kinetic studies on
E172-173 and E196-301 under the same experimental conditions and compared their
catalytic efficiency against (-)-cocaine. Michaelis-Menten kinetics of the enzymatic
hydrolysis of (−)-cocaine was determined by performing the sensitive radiometric assays
using [3H](−)-cocaine (labeled on its benzene ring) with varying concentrations of the
substrate. Depicted in Figure 6.3 are the measured kinetic data, and summarized in Table
6.2 are the determined kinetic parameters.

Figure 6.3 Plots of measured reaction rates (with error bars) versus the substrate
concentration for (−)-cocaine hydrolysis catalyzed by CocE mutants. (A) E196-301, 25°C,
(B) E196-301, 37°C, (C) E172-173, 25°C, (D) E172-173, 37°C. E172-173 refers to
T172R/G173Q CocE mutation, and E196-301 refers to T172R/G173Q/L196C/I301C
CocE mutation.
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Table 6.2 Kinetic parameters determined for (-)-cocaine hydrolysis catalyzed by CocE
mutants.
KM

kcat

kcat/KM

T

(µM)

(min-1)

(M-1min-1)

(°C)

E196-301

2.4

1950

8.2×108

E172-173

4.5

1400

3.13×108

E196-301

1.5

3450

2.30×109

E172-173

2.9

2600

9.15×10-8

Enzymea

a

25

37

E172-173 refers to T172R/G173Q CocE mutation, and E196-301 refers to

T172R/G173Q/L196C/I301C CocE mutation.

After determination of the kinetic parameters of E196-301, the purified protein
was assessed for thermostability. As seen in Figure 6.4, the enzyme showed a relatively
fast decrease of the activity (around 20%) in the first few days. Though the disulfide
bonds were expected to form spontaneously (no extra oxidation reagent was employed
here to facilitate the formation), a small percent of the new mutant (E196-301) molecules
did not form the desirable cross-subunit disulfide bonds. Those E196-301 molecules
without the desirable cross-subunit disulfide bonds could lose the activity more rapidly.
The in vitro half-life of the new mutant without cross-subunit disulfide bonds is expected
to the same as that of E172-173 which is ~6 hr (at 37oC).62 However, starting from the
ninth day, the further enzyme activity in the subsequent 90 days was only about 15%,
demonstrating its high thermostability. Overall, the enzyme still retained more than 60%
of enzymatic activity after incubation at 37°C for 100 days, indicating that its in vitro
half-life at 37°C is longer than 100 days.
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Figure 6.4 Thermostability profile of E196-301. Percentage of the remaining enzyme
activity was plotted against days (0, 2, 9, 12, 31, and 100 days) of incubation at 37 °C.
E196-301 refers to T172R/G173Q/L196C/I301C CocE.

The circular dichroism measurements of thermal denaturation were performed to
detect the apparent denaturation temperature (Tm) of E172-173 and E196-301. According
to the data in Figure 6.5, the Tm value of E172-173 and E196-301 are ~47°C and ~49°C,
thus E196-301 has a ~2°C elevated Tm compared with E172-173.
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Figure 6.5 Date from circular dichroism measurements of E172-173 and E196-301.
E172-173 refers to the T172R/G173Q CocE, and E196-301 refers to the
T172R/G173Q/L196C/I301C CocE.

6.7 Confirmation of new cross-subunit disulfide bond(s) between the subunits
The above experimental results suggest the formation of the designed crosssubunit disulfide bonds in the CocE dimer. Further, in collaboration with Dr. David
Rodgers, we tried to obtain the crystal structure of E196-301 that can be used to directly
confirm the formation of the cross-subunit disulfide bonds between L196 and I301 (the
detailed experimental procedure will be described elsewhere). The obtained X-ray crystal
structure of E196-301 is depicted in Figure 6.6 in comparison with that of E172-173.
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Figure 6.6 Backbone alignments between the crystal structures of E172-173 and E196301. E172-173 is represented in green ribbons, and E196-301 is represented in red
ribbons. The black arrow indicates the shift direction. E172-173 refers to T172R/G173Q
CocE, and E196-301 refers to T172R/G173Q/L196C/I301C CocE.

Figure 6.6 shows the alignment between E172-173 and E196-301 with a RMSD
value of 0.299 Å, indicating the high similarity of the structures. However, the alignment
result also shows a slight shift of two α-helices (H2 and H3 in domain II) in E196-301
compared with that in E172-173 as indicated by the arrows in Figure 6.6. The shift
created a slightly enlarged active-site cavity in E196-301, which could possibly facilitate
the catalytic reaction. A slightly larger active site could accommodate such a large
substrate (cocaine) better and, thus, make the enzyme more active against cocaine; the
similar mechanism was noted for the catalytic activity of certain BChE mutants against
cocaine.105
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Figure 6.7 Time-dependence of important HO distances (related to hydrogen bonds)
from the MD-simulated E172-173 and E196-301 structures. Y44HH–CocO represents the
distance between the hydroxyl hydrogen (HH) of the Y44 side chain and the oxygen atom
(CocO) of carbonyl oxygen of (–)-cocaine benzoyl ester. Y118H–CocO refers to the
distance between hydrogen (H) of the Y118 main chain and the oxygen atom (CocO) of
carbonyl oxygen of (–)-cocaine benzoyl ester. E172-173 refers to T172R/G173Q CocE,
and E196-301 refers to T172R/G173Q/L196C/I301C CocE.

Table 6.3 Summary of the MD-simulated key distances (in Å) between the hydrogen
atoms of key residue and the carbonyl oxygen of (–)-cocaine benzoyl ester in the
transition-state structures of CocE.
Distances
Hydrogen bond
Y44HH-CocO
Y118H-CocO
a

E172-173

refers

Maximum
(Å)

E172-173a
3.02
a
E196-301
3.17
E172-173a
3.14
a
E196-301
2.89
to T172R/G173Q CocE,

Minimum
(Å)

Average
(Å)

1.44
1.44
1.61
1.61
and E196-301

1.87
1.80
2.16
2.13
refers

to

T172R/G173Q/L196C/I301C CocE.

To further examine the possible mechanism concerning the improved catalytic
activity, MD simulations were performed on the transition-state structures (TS1’s) of
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E172-173 and E196-301. Depicted in Figure 6.7 are the simulated time-dependent HO
distances (related to the hydrogen bonds) in E172-173 and E196-301 during the MD
simulations for 50 ns. The detailed analysis of the key HO distances between enzyme
residues and cocaine is summarized in Table 6.34. In E172-173, the HO distance of
CocO with Y44HH is 3.02 Å in maximum, 1.44 Å in minimum, and 1.87 Å in average,
while the HO distance with Y114 is 3.14 Å in maximum, 1.61 Å in minimum, and 2.16
Å in average. In E196-301, the HO distance between Y44HH and CocO is 3.17 Å in
maximum, 1.44 Å in minimum, and 1.80 Å in average, whereas the HO distance
between Y114H and CocO is 2.89 Å in maximum, 1.61 Å in minimum, and 2.13 Å in
average. According to these HO distances, the lengths of the two hydrogen bonds in
E196-301 are shorter than the corresponding ones in E172-173, suggesting that cocaine
has stronger hydrogen bonding with E196-301 compared to that with E172-173. The
enhanced hydrogen bonding helps to stabilize the transition-state structure during the
catalytic reaction and, thus, lower the energy barrier, which explains the improved
catalytic activity of the new mutant.

6.8 in vivo protection against cocaine-induced lethality in mice
After confirming the high thermostability of the E196-301, the PEGylation
modification was conducted to further engineer E196-301. According to the activity
assays, the PEGylated E196-301 maintained its activity against cocaine as that of E196301. To test the ability of E196-301 and PEGylated E196-301 in protecting mice from a
lethal dose of cocaine, E196-301 or PEGylated E16-301 was administered intravenously
(at a single dose of 30 mg/kg) 1 min before the first intraperitoneal administration of 180
mg/kg cocaine (n=5). Depicted in Figure 6.8 are the data for the in vivo protection of
unPEGylated E196-301 and PEGylated E196-301 against cocaine-induced lethality in
mice. As seen in Figure 6.8, unPEGylated E196-301 protected the mice from death after
the first injection of 180 mg/kg cocaine, but lost efficacy at second injection of 180
mg/kg cocaine 24 hours later. PEGylated E196-301 performed much better. It fully
protected all the mice (n=5) for at least 72 hr from the acute toxicity of a lethal dose of
cocaine (180 mg/kg, LD100): no mice died during the cocaine challenge at 72 hr, three
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mice died during the cocaine challenge at 96 hr, and the remaining two mice died during
the final cocaine challenge at 120 hr (see Figure 6.8). According to the data depicted in
Figure 6.8, PEGylated E196-301 can protect the three mice (60%) with the protection
time (tp) being between 72 hr and 96 hr: 72 hr < tp < 96 hr, or we have tp = 84±12 hr. For
the remaining two mice (40%), 96 hr < tp < 120 hr, or we have tp = 108±12 hr according
to the data in Figure 6.8. Overall, PEGylated E196-301 can protect the mice with an
average protection time (<tp>) of ~94 hr, i.e. we have <tp> = ~94 hr.

Figure 6.8 in vivo protection of E196-301 (black squares) and PEGylated E196-301 (red
triangles) against cocaine-induced lethality in mice. A single dose (30 mg/kg) of E196301 or PEGylated E16-301 was administered intravenously 1 min before the first
intraperitoneal administration of 180 mg/kg cocaine (n=5). The mice were challenged
daily with 180 mg/kg cocaine via intraperitoneal administration until no mouse survived.
E196-301 refers to T172R/G173Q/L196C/I301C CocE.

6.9 Conclusion
In the study described in this chapter, molecular dynamics simulation on the
dimer structure of a promising cocaine–metabolizing enzyme, i.e. E172-173 engineered
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from wild-type CocE, led us to predict that the extra L196C/I301C mutations on E172173 can produce cross-subunit disulfide bonds in the enzyme and, thus, stabilize the
dimer structure. Following the computational prediction, our in vitro experimental studies
have

demonstrated

that

the

computationally

designed

new

CocE

mutant

(T172R/G173Q/L196C/I301C), i.e. E196-301, indeed has significantly improved
thermostability and catalytic activity against cocaine. in vivo tests showed that the
PEGylated E196-301 can fully protect mice from a lethal dose of cocaine (180 mg/kg,
LD100) for at least three days, whereas the unPEGylated E196-301 can only protect mice
less than 24 Hours. In summary, the newly designed and discovered CocE mutant E196301 could be more valuable than E172-173 in the future development of a novel enzyme
therapy for cocaine abuse. The encouraging outcomes of the study described in this
chapter suggest that the structure-and-mechanism-based computational design and
integrated computational-experimental approach are promising for rational protein drug
design, discovery, and development. The general computational protein design strategy
and approach may also be valuable for engineering other proteins.

Copyright @ Lei Fang 2013
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Chapter Seven: Concluding Remarks and Future Plan

Human butyrylcholinesterase (BChE) and bacterial cocaine esterase (CocE) have
shown their potential in treating cocaine abuse. However, the wild-type enzymes
themselves are not suitable for use as anti-cocaine therapeutics, due to the low catalytic
activity, thermoinstability, and/or short biological half-life. In this investigation, we
performed integrated computational-experimental studies to rationally design and
discover mutants of these enzymes in order to improve the catalytic activity,
thermostability, and/or biological half-life. To rationally design desirable mutants of the
enzymes, we have successfully developed computational models, including those for the
BChE gating, glycosylated BChE structure, BChE-substrate complex structure, BChE
dimer/tetramer structures, CocE monomer/dimer structures, and CocE-substrate complex
structures. Development of the computational models enabled us to rationally design new
amino-acid mutations that may improve catalytic activity, thermostability, and/or
biological half-life. The computational design was followed by wet experimental tests,
including both in vitro and in vivo experiments, leading to encouraging outcomes.

7.1 Summary of the major conclusions obtained from this investigation
1) The active sites and gating mechanisms of AChE and BChE have been
compared by performing MD simulations on the water-solvated systems of the monomers
and tetramers of hBChE and AChE. It has been demonstrated that different gating
mechanisms due to the conformational dynamics of gating residues of AChE and BChE
are responsible for their difference in the substrate specificity. The MD simulations of the
tetramer structures of AChE and BChE have revealed that although there are some
structural differences, both enzymes have a common feature that they could have two
dysfunctional active sites due to the special locations of the active-site gate.
2) According to the BChE-substrate complex models, the computationally
designed mutations only considerably improve the catalytic efficiency of human BChE
against (-)-cocaine, without significantly improving the catalytic activities against other
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substrates (including acetylcholine, acetylthiocholine, butyrylthiocholine, and (+)cocaine).
3) A 3D structural model of the glycosylated human BChE has been developed to
examine the possible effects of the glycosylation on the possible PEGylation
modification reactions, revealing the direct and indirect influence of the glycosylation.
4) The computationally designed new mutations (F364C/M532C, V377C/A516C,
and

N535C)

have

successfully

extended

the

biological

half-life

of

A199S/F227A/S287G/A328W/Y332G BChE in rats from ~7 hr to ~13 hr, without
significantly

changing

the

high

catalytic

activity

of

A199S/F227A/S287G/A328W/Y332G BChE against (-)-cocaine.
5) The computationally designed new mutations (L196C/I301C) have
successfully extended the in vitro half-life of T172R/G173Q CocE from ~6 hrs. to at least
100 days, and significantly improved the catalytic activity against cocaine. In addition, it
has been demonstrated that the PEGylated T172R/G173Q/L196C/I301C CocE can be
used to fully protect mice from a lethal dose of cocaine (180 mg/kg, LD100) for at least
three days.

7.2 Future plan concerning rational design of therapeutic enzymes for cocaine abuse
Future rational design of human BChE mutants should be focused on improving
the biological half-life while maintaining the high catalytic activity against (-)-cocaine
and selectivity for (-)-cocaine over neurotransmitter acetylcholine.
For CocE-based protein drug design, future rational design should be focused on
improving the biological half-life and reducing the immune response. In addition,
improving the catalytic efficiency of the thermostable CocE mutants against (-)-cocaine
may be another direction, and the substrate selectivity of the thermostable CocE mutants
for (-)-cocaine over neurotransmitter acetylcholine should also be accounted for in the
computational design.

Copyright @ Lei Fang 2013
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